(S1 (S (S (NP (NP (NN -LSB-Interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (-RRB- -RSB-)) (. .)))
(S1 (S (S (NP (NP (DT The) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (NP (NP (DT the) (NN subject)) (PP (IN of) (NP (JJ much) (NN study))) (PP (IN in) (NP (JJ recent) (NNS years))))))) (. .)))
(S1 (S (S (NP (NP (JJ Contradictory) (NNS results)) (VP (VBG regarding) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN on) (NP (NN platelet) (NN reactivity))) (CC and) (PP (IN on) (NP (NP (JJ clinical) (NN outcome)) (PP (IN in) (NP (CD drug2) (JJ -treated) (NNS patients))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NN literature))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD was) (VP (VBN found) (S (VP (VP (TO to) (VP (VB decrease) (NP (NP (NP (DT the) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN AUC)) (-RRB- -RRB-))) (PP (TO to) (NP (NN clopidogrel) (POS 's) (JJ active) (NN metabolite)))) (PP (IN by) (NP (CD 50) (NN %))))) (CC and) (VP (TO to) (ADVP (RB sharply)) (VP (VB increase) (NP (NN platelet) (NN reactivity)) (, ,) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN by) (NP (NP (NN drug3)) (PP (IN of) (NP (NP (NN CYP2C19)) (, ,) (NP (DT a) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NN enzyme))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT a) (ADJP (RB much) (JJR weaker)) (NN effect)) (PP (PP (IN on) (NP (NN drug2) (POS 's) (NNS pharmacokinetics))) (CC and) (PP (IN on) (NP (NP (NN platelet) (NN reactivity)) (PP (IN during) (NP (JJ concomitant) (NN use))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NP (DT the) (JJ other) (NN drug1)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN drug2))))))))) (VP (VBZ has) (RB not) (ADVP (RB yet)) (VP (VBN been) (VP (VBN investigated) (PP (IN in) (NP (ADJP (RB adequately) (JJ randomized)) (NNS studies))))))) (. .)))
(S1 (S (S (NP (JJ Regulatory) (NNS agencies)) (VP (NN state) (SBAR (IN that) (S (NP (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (NN CYP2C19) (NNS inhibitors)) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))))) (. .)))
(S1 (S (S (PP (TO To) (NP (NN date))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (JJ conclusive) (NN evidence)) (PP (IN of) (NP (NP (DT a) (JJ clinically-relevant) (NN interaction)) (PP (IN between) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))) (, ,) (PP (IN in) (NP (JJ human) (NN A375) (NN melanoma) (NNS cells))))) (. .))))
(S1 (S (NP (PRP We)) (VP (VBD evaluated) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NP (DT the) (JJ alkyating) (NN agent) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ pro-oxidant)) (, ,) (NP (NN drug3)) (, ,)))))) (PP (IN in) (NP (DT the) (JJ human) (NN A375) (NN melanoma) (NN cell) (NN line))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (, ,) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NN combination)))) (, ,)) (VP (VBD was) (VP (VBN evaluated) (PP (IN for) (NP (NP (NP (NN growth) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NN MTT)) (-RRB- -RRB-))) (, ,) (NP (VBN radiolabeled) (NN drug) (NN uptake)) (, ,) (NP (NP (JJ cellular) (NN thiol) (NN content)) (PRN (-LRB- -LRB-) (NP (NN HPLC)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN DNA) (NN strand) (NNS breaks)) (PRN (-LRB- -LRB-) (NP (NN Comet) (NN assay)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Pharmacokinetic)) (CC and) (ADJP (JJ antitumor))) (NNS effects)) (VP (VBD were) (VP (VBN evaluated) (PP (IN in) (NP (NNS mice)))))) (. .)))
(S1 (S (S (NP (NP (NN Growth) (NN inhibition)) (ADVP (FW in) (FW vitro))) (VP (VBD was) (ADJP (JJ additive) (PP (IN with) (NP (DT the) (CD two) (NNS drugs)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (PP (IN on) (NP (NN drug) (NN uptake))) (CC or) (PP (IN on) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN DNA) (NN strand) (NNS breaks))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (CD >75) (NN %) (NN reduction)) (PP (IN in) (NP (NP (JJ cellular) (NN glutathione)) (CC and) (NP (NN cysteine)))) (PP (IN with) (NP (NP (NN drug1)) (CONJP (CC but) (RB not)) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (DT the) (CD two) (NNS drugs))) (PP (IN in) (NP (NNS mice)))) (VP (VBD caused) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (DT the) (NN curve)) (PP (IN of) (NP (DT both) (NNS drugs)))))))))) (, ,) (CC but) (S (NP (DT the) (NN combination)) (VP (VBD was) (RB not) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG reducing) (NP (JJ human) (NN A375) (NN melanoma) (NNS tumors)) (ADVP (FW in) (FW vivo)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP show) (NP (JJ additive) (NNS effects)) (ADVP (FW in) (FW vitro) (CONJP (CC but) (RB not)) (ADVP (FW in) (FW vivo))) (PP (IN in) (NP (JJ human) (NN A375) (NN melanoma) (NNS cells))))) (. .)))
(S1 (S (S (NP (NP (NN Enhancement)) (PP (IN of) (NP (NP (JJ humoral) (JJ immune) (NNS responses)) (PP (TO to))))) (VP (VBD inactivated) (NP (NP (JJ Newcastle) (NN disease)) (CC and) (NP (NN drug1))) (PP (IN by) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PP (IN in) (NP (NNS chickens))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Newcastle) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ND)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ avian) (NN influenza)) (PRN (-LRB- -LRB-) (NP (NN AI)) (-RRB- -RRB-)))) (VP (VBP are) (ADJP (JJ common) (PP (IN in) (NP (DT the) (NN poultry) (NN industry)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (DT the) (JJ humoral) (JJ immune) (NNS responses)) (PP (IN of) (NP (NNS chickens))) (PP (TO to) (NP (NP (NN drug3)) (CC and) (NP (NN drug4) (NN drug4)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN experiment) (CD 1))) (, ,) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 5) (NN mg/kg)) (PP (IN of) (NP (NN BW))) (PP (IN for) (NP (CD 7) (NN d))) (PP (IN on) (NP (NP (DT the) (JJ immune) (NN response)) (PP (IN in) (NP (NP (NNS chickens)) (VP (ADVP (RB intramuscularly)) (VBN injected) (PP (IN with) (NP (NN drug2))))))))))))) (VP (VBD was) (VP (VBN evaluated))) (. .)))
(S1 (S (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (NN antibody) (NN level)) (PP (IN against) (NP (NN ND))) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (NNS chickens))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN experiment) (CD 2))) (, ,) (S (NP (NP (DT the) (JJ same) (NN regimen)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (NNS chickens)) (VP (VBN inoculated) (PP (IN with) (NP (NN drug2))))))))) (, ,) (CC and) (S (NP (NP (DT an) (VBN enhanced) (NN serum) (NN antibody) (NN response)) (PP (TO to) (NP (NN AI) (NN vaccination)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed))))) (. .)))
(S1 (S (S (VP (VBG Considering) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NN drug1)))))) (, ,) (S (SBAR (IN because) (S (NP (DT no) (JJ adverse) (NN effect)) (VP (VBD was) (VP (VBN found) (PP (IN throughout) (NP (DT the) (NNS experiments))))))) (, ,) (NP (NN drug2)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ promising) (JJ oral) (JJ adjuvant)) (S (VP (TO to) (VP (VB improve) (NP (NN immunization)) (PP (IN in) (NP (NN poultry)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN against) (NP (NP (DT the) (JJ acute) (NN toxicity)) (PP (IN of) (NP (NP (NN diepoxybutane)) (PP (TO to) (NP (JJ human) (NNS lymphocytes))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN biotransformation)) (CC and) (NP (JJ oxidative) (NN stress))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (ADJP (NN 1,2:3,4-diepoxybutane) (-LRB- -LRB-) (NN DEB) (-RRB- -RRB-) (JJ -induced)) (NN toxicity))) (PP (TO to) (NP (NP (JJ human) (NNS lymphocytes)) (PP (IN of) (NP (NP (NP (NNP Fanconi) (NN Anemia)) (PRN (-LRB- -LRB-) (NP (NN FA)) (-RRB- -RRB-))) (NNS patients)))))))) (. .)))
(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (JJ putative) (NNS inhibitors)) (PP (IN of) (NP (NN bioactivation)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (JJ oxidant) (NNS defenses)))))) (, ,) (PP (IN on) (NP (JJ DEB-induced) (NN toxicity))) (, ,)) (VP (MD can) (VP (VB help) (S (VP (TO to) (VP (VB understand) (SBAR (WHNP (WP what)) (S (VP (VBZ is) (VP (VBG failing) (PP (IN in) (NP (NN FA) (NNS cells)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN work))) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (JJ several) (JJ biochemical) (NNS pathways))) (PP (IN for) (NP (NP (JJ DEB-induced) (JJ acute) (NN toxicity)) (PP (IN in) (NP (JJ human) (NN lymphocyte) (NNS suspensions)))))) (, ,) (PP (IN by) (S (VP (VBG using) (NP (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN epoxide) (NNS hydrolases)))) (, ,) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (JJ protective) (NNS enzymes)) (PP (IN as) (NP (NP (NN glutathione) (NN S-transferase)) (CC and) (NP (NN catalase))))))) (, ,) (NP (NP (DT the) (NN depletion)) (PP (IN of) (NP (NP (NN glutathione)) (PRN (-LRB- -LRB-) (NP (NN GSH)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN protein) (NN synthesis)))))))))) (: ;)))
(S1 (S (S (NP (CC and) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ putative) (JJ protective) (NNS compounds)) (, ,) (PP (VBG including) (NP (NNS antioxidants))) (, ,)))) (CC and) (NP (JJ mitochondrial) (JJ protective) (NNS agents)))) (. .)))
(S1 (S (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ reports) (NP (CD two) (JJ novel) (NNS findings)))) (: :) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (PRP it)) (VP (VBD was) (ADVP (RB clearly)) (VP (VBN evidenced) (, ,) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (, ,) (SBAR (IN that) (S (NP (NP (DT the) (JJ acute) (NN exposure)) (PP (IN of) (NP (ADJP (RB freshly) (VBN isolated)) (JJ human) (NNS lymphocytes))) (PP (TO to) (NP (NN DEB)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ severe) (NN GSH) (NN depletion)) (CC and) (NP (NP (NN loss)) (PP (IN of) (NP (NN ATP)))))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NN cell) (NN death))))))))))) (: ;)))
(S1 (S (S (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NN drug1)) (VP (VBZ elicits) (NP (NP (DT a) (JJ significant) (JJ protective) (NN effect)) (PP (IN on) (NP (NN DEB) (JJ induced) (NN toxicity))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2)))))))))) (. .)))
(S1 (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS findings)) (VP (VP (VBP contribute) (S (VP (TO to) (VP (VB increase) (NP (NP (PRP$ our) (NN knowledge)) (PP (IN of) (NP (JJ DEB-induce) (NN toxicity)))))))) (CC and) (VP (MD will) (VP (VB be) (ADJP (RB very) (JJ useful) (SBAR (WHADVP (WRB when)) (S (VP (VBN applied) (PP (IN in) (NP (NP (NNS studies)) (PP (IN with) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ FA) (NNS patients)))))))))))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (NP (NP (DT a) (JJ protective) (NN agent)) (PP (IN against) (NP (ADJP (ADJP (JJ spontaneous)) (CC and) (ADJP (JJ DEB-induced))) (NN chromosome) (NN instability)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Metabotropic) (NN glutamate) (NN receptor) (CD 5)) (NN antagonist)) (VP (VBZ protects) (NP (ADJP (ADJP (JJ dopaminergic)) (CC and) (ADJP (JJ noradrenergic))) (NNS neurons)) (PP (IN from) (NP (NP (NN degeneration)) (PP (IN in) (NP (JJ drug1) (JJ -treated) (NNS monkeys))))))) (. .)))
(S1 (S (S (NP (NP (NN Degeneration)) (PP (PP (IN of) (NP (DT the) (JJ dopaminergic) (JJ nigrostriatal) (NN system))) (CC and) (PP (IN of) (NP (NP (JJ noradrenergic) (NNS neurons)) (PP (IN in) (NP (DT the) (NN locus) (NN coeruleus))))))) (VP (VBP are) (NP (NP (JJ important) (JJ pathological) (NNS features)) (PP (IN of) (NP (NP (NN Parkinson) (POS 's)) (NN disease)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT an) (JJ urgent) (NN need)) (S (VP (TO to) (VP (VB develop) (NP (NP (NNS therapies)) (PP (IN that) (NP (NP (JJ slow) (JJ down) (DT the) (NN progression)) (PP (IN of) (NP (NN neurodegeneration))) (PP (IN in) (NP (NP (NN Parkinson) (POS 's)) (NN disease)))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD tested) (SBAR (IN whether) (S (NP (NP (DT the) (ADJP (RB highly) (JJ specific)) (NP (JJ metabotropic) (NN glutamate) (NN receptor) (CD 5)) (NN antagonist)) (, ,) (NP (NN drug1)) (, ,)) (VP (VBZ reduces) (NP (ADJP (ADJP (JJ dopaminergic)) (CC and) (ADJP (JJ noradrenergic))) (JJ neuronal) (NN loss)) (PP (IN in) (NP (NP (NNS monkeys)) (VP (VBN rendered) (NP (NN parkinsonian)) (PP (IN by) (NP (NP (JJ chronic) (NN treatment)) (PP (IN with) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (NP (NP (JJ Weekly) (NN intramuscular) (NN drug1) (NNS injections)) (PRN (-LRB- -LRB-) (NP (CD 0.2-0.5) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN vehicle)))))))) (, ,) (VP (VBD were) (VP (VBN performed) (PP (IN until) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ parkinsonian) (NN motor) (NNS symptoms)) (PP (IN in) (NP (NP (DT either)) (PP (IN of) (NP (NP (DT the) (CD two) (JJ experimental) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (: /) (NP (NN drug4)) (CC versus) (NP (NN drug5) (NN /vehicle))) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (S (PP (IN After) (NP (NP (CD 21) (NNS weeks)) (PP (IN of) (NP (NN drug1) (NN treatment))))) (, ,) (NP (DT all) (NN drug2) (JJ /vehicle-treated) (NNS animals)) (VP (VBD displayed) (NP (JJ parkinsonian) (NNS symptoms)))) (, ,) (IN whereas) (S (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NN drug3) (: /) (NN drug4) (JJ -treated) (NNS monkeys)))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN affected))))) (. .)))
(S1 (S (S (NP (DT These) (JJ behavioural) (NNS observations)) (VP (VBD were) (ADJP (JJ consistent) (PP (PP (IN with) (NP (NP (NP (ADJP (FW in) (FW vivo)) (NN positron) (NN emission) (NN tomography)) (NN dopamine) (NN transporter)) (VP (VBG imaging) (NP (NNS data))))) (, ,) (CC and) (PP (IN with) (NP (NP (JJ post-mortem) (JJ stereological) (NNS counts)) (PP (IN of) (NP (JJ midbrain) (JJ dopaminergic) (NNS neurons)))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ striatal) (NN intensity) (NNS measurements)) (PP (IN of) (NP (NP (NP (NN dopamine) (NN transporter)) (CC and) (NP (NP (NN tyrosine) (NN hydroxylase)) (NN immunoreactivity))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (ADVP (RB all)) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN drug1) (: /) (NN drug2) (JJ -treated) (NNS animals))) (PP (IN than) (PP (IN in) (NP (CD drug3) (JJ /vehicle-treated) (NNS monkeys)))))))))))) (. .)))
(S1 (S (NP (DT The) (NN drug1) (NN treatment)) (ADVP (RB also)) (VP (VBD had) (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (ADJP (NN drug2) (JJ -induced)) (NN loss)) (PP (IN of) (NP (NP (NN norepinephrine) (NNS neurons)) (PP (IN in) (NP (NP (NP (DT the) (NN locus) (NN coeruleus)) (CC and) (NP (JJ adjoining) (NN A5) (CC and) (NN A7) (NN noradrenaline))) (NN cell) (NNS groups)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN drug1) (JJ /vehicle-treated) (NNS animals))) (, ,) (NP (NP (ADJP (QP (RB almost) (CD 40)) (NN %)) (NN loss)) (PP (IN of) (NP (ADJP (NN tyrosine) (JJ hydroxylase-positive)) (NN norepinephrine) (NNS neurons)))) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (NN locus) (NN coeruleus/A5/A7) (NN noradrenaline) (NN cell) (NNS groups)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ neuronal) (NN loss)))) (VP (VBD was) (NP (NP (QP (JJR lower) (IN than) (CD 15)) (NN %)) (PP (IN of) (NP (NN control) (NNS values)))) (PP (IN in) (NP (NN drug2) (: /) (NN drug3) (JJ -treated) (NNS monkeys))))))) (. .)))
(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ chronic) (NN treatment)) (PP (IN with) (NP (NP (NP (DT the) (JJ metabotropic) (NN glutamate) (NN receptor) (CD 5)) (NN antagonist)) (, ,) (NP (NN drug1)) (, ,)))) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NN drug2) (NN toxicity)) (PP (IN towards) (NP (ADJP (ADJP (JJ dopaminergic)) (CC and) (ADJP (JJ noradrenergic))) (NN cell) (NNS groups))) (PP (IN in) (NP (JJ non-human) (NNS primates)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ metabotropic) (NN glutamate) (NN receptor) (CD 5) (NNS antagonists)))) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ useful) (NN strategy)) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN degeneration)) (PP (IN of) (NP (JJ catecholaminergic) (NNS neurons))) (PP (IN in) (NP (NP (NN Parkinson) (POS 's)) (NN disease)))))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN activity)) (PP (IN of) (NP (NN drug1)))) (VP (VBN combined) (PP (IN with) (NP (NP (NN drug2)) (PP (IN against) (NP (NP (JJ clinical) (NNS isolates)) (PP (IN of) (NP (NP (NN drug3)) (ADJP (JJ -resistant) (ADVP (FW Staphylococcus) (FW aureus))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (ADJP (FW in) (FW vitro)) (NN activity)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN combined) (PP (IN with) (NP (NP (NN drug2)) (PP (IN against) (NP (NP (NNS isolates)) (PP (IN of) (NP (NP (CD drug3) (JJ -resistant) (NP (FW Staphylococcus) (FW aureus))) (PRN (-LRB- -LRB-) (NP (NN MRSA)) (-RRB- -RRB-))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 87) (JJ clinical) (NNS isolates)) (PP (IN of) (NP (NN MRSA))) (VP (VBN collected) (PP (IN from) (NP (CD three) (JJ Chinese) (NNS hospitals))))))) (VP (VBD were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ checkerboard) (NN method)) (PP (IN with) (NP (NP (NN determination)) (PP (IN of) (NP (NP (DT the) (JJ fractional) (NN IC) (NN index)) (PRN (-LRB- -LRB-) (NP (NN FICI)) (-RRB- -RRB-))))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN drug1) (NNS combinations)) (VP (VBP act) (ADVP (RB synergistically)) (PP (IN against) (NP (DT these) (NNS isolates)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN susceptibility) (NNS results)) (PP (IN for) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBD were) (VP (VBN interpreted) (PP (VBG according) (PP (TO to) (NP (DT the) (ADJP (RBS most) (JJ relevant)) (NNS criteria))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD demonstrated) (NP (DT the) (JJ following) (NNS interactions)))) (: :) (S (NP (NP (CD 76) (NNS isolates)) (PRN (-LRB- -LRB-) (NP (CD 87.4) (NN %)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (NP (JJ synergistic) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NNP FICI) (CD 0.5)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 11) (NNS isolates)) (PRN (-LRB- -LRB-) (NP (CD 12.6) (NN %)) (-RRB- -RRB-)))) (VP (VBD showed) (NP (NP (JJ indifferent) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NP (NN 0.5&amp)) (: ;) (NP (NN lt)) (: ;) (NP (NN FICI&amp)) (: ;) (NP (NN lt)) (: ;) (NP (CD 4))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ antagonistic) (NNS interactions)) (PRN (-LRB- -LRB-) (NP (NNP FICI) (CD 4)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD can) (VP (VB be) (ADJP (JJ synergistic) (PP (IN against) (NP (NN MRSA))))))) (. .)))
(S1 (S (S (NP (JJ Further) (NNS studies)) (VP (VBP are) (VP (VBN required) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (ADJP (ADJP (JJ potential)) (ADJP (JJ clinical))) (NN role)) (PP (IN of) (NP (DT this) (NN combination) (NN regimen))) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN alternative)) (PP (IN for) (NP (NP (JJ certain) (NNS types)) (PP (IN of) (NP (NN MRSA) (NNS infections)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ enhances) (NP (ADJP (NN drug2) (JJ -mediated)) (JJ antibody-dependent) (JJ cellular) (NN cytotoxicity)) (PP (IN by) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN cell) (NN surface) (NN HER2) (NN expression))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (PRP it)) (VP (VBD was) (ADVP (RB previously)) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (NN drug1)) (VP (VBN combined) (PP (IN with) (NP (NN drug2))))) (VP (VBD improved) (NP (DT the) (JJ progression-free) (NN survival) (NN rate)) (PP (VBN compared) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone))))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug4) (JJ -refractory) (JJ HER2-positive) (JJ metastatic) (NN breast) (NN cancer)))))))))))) (, ,) (NP (DT the) (NN mechanism)) (VP (VBZ is) (VP (VBN purported) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (JJ antiproliferative) (NN effect)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NN synergism)) (PP (IN of) (NP (DT these) (CD two) (NNS agents))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD evaluated) (SBAR (WHADVP (WRB how)) (S (NP (NN drug1)) (VP (VBZ interacts) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (JJ HER2-positive) (NN breast) (NN cancer))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ particular) (NN focus)) (PP (IN on) (NP (NP (NN drug3) (JJ -mediated) (JJ antibody-dependent) (JJ cellular) (NN cytotoxicity)) (PRN (-LRB- -LRB-) (NP (NN ADCC)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN assay))) (, ,) (NP (NN drug1)) (VP (VBD induced) (NP (NN HER2) (NN expression)) (PP (IN at) (NP (NP (DT the) (NN cell) (NN surface)) (PP (IN of) (NP (JJ HER2-positive) (NN breast) (NN cancer) (NN cell) (NNS lines))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (NN drug2) (JJ -mediated) (NN ADCC))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (NN case) (NN report)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (JJ second) (NN drug1) (NN treatment)) (PP (VBG following) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (JJ marked) (NN shrinkage)) (PP (IN of) (NP (NP (JJ multiple) (JJ metastatic) (NNS tumors)) (PP (IN in) (NP (JJ HER2-positive) (NN breast) (NN cancer))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VBP convert) (NP (NN drug2) (NN -refractory)) (PP (TO to) (NP (NP (NN drug3) (JJ -sensitive) (NNS tumors)) (PP (IN in) (NP (JJ HER2-positive) (NN breast) (NN cancer))))))))) (PP (IN by) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NP (DT the) (NN cell) (NN surface) (NN expression)) (PP (IN of) (NP (NN HER2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Improved) (NP (JJ parathyroid) (NN hormone)) (NN control)) (PP (IN by) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN drug2) (NN requirement)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ end-stage) (JJ renal) (NN disease)))))))))))) (. .)))
(S1 (S (S (NP (JJ Uncontrolled) (NN hy-per-parathyroidism)) (VP (VBZ causes) (NP (NP (NN bone) (NN marrow)) (NN fibrosis)) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (NN resistance))))))) (. .)))
(S1 (S (S (S (NP (NP (JJ Medical) (NN treatment)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ is) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG reducing) (NP (NP (NP (NN plasma) (JJ parathyroid) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN PTH)) (-RRB- -RRB-))) (NNS levels)))))))) (, ,) (CC but) (S (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (NN drug2) (NN dosing)))) (VP (VBZ is) (ADJP (JJ unknown))))) (. .)))
(S1 (S (NP (NP (NP (NNS METHODS)) (CC AND) (NP (NNS AIMS))) (: :) (S (NP (PRP We)) (VP (VBN conducted) (NP (NP (DT a) (JJ retrospective) (NN cohort) (NN study)) (PP (IN of) (NP (NP (NP (CD 40) (NP (NP (JJ end-stage) (JJ renal) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ESRD)) (-RRB- -RRB-))) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN age)) (: :) (NP (NP (CD 55)) (CD 14) (: ;) (NN mean) (NN SD)) (: ;) (NP (CD 21)) (: :) (NP (NN male))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (NP (QP (IN at) (JJS least) (CD 12)) (NNS months)) (PP (IN of) (NP (NN drug1) (NN therapy)))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN distribution)) (PP (IN of) (NP (JJ renal) (NN replacement) (NNS therapies)))) (VP (VBD were) (: :) (NP (NP (CD 14) (JJ peritoneal) (NNS dialysis)) (, ,) (NP (NP (CD 18) (JJ conventional) (NN hemodialysis)) (CC and) (NP (CD 8) (JJ nocturnal) (NN hemodialysis)))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Standard) (NN dialysis) (JJ related) (JJ biochemical) (NNS indices)) (CC and) (NP (NNS medications))) (VP (VBN used))) (VP (VBD were) (VP (VBN recorded)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ primary) (NN objective)) (PP (IN of) (NP (DT the) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB ascertain) (NP (NP (DT the) (NN difference)) (PP (IN in) (NP (NN drug1) (NN responsiveness))) (PP (PP (IN before)) (CC and) (PP (IN after) (NP (NP (CD 12) (NNS months)) (PP (IN of) (NP (NN drug2) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (JJ secondary) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NN PTH)) (CC and) (NP (NN drug1) (NN requirement))))))))))))))) (. .)))
(S1 (S (ADVP (RB Overall)) (, ,) (NP (NN PTH) (NNS levels)) (VP (VBD decreased) (PP (IN from) (NP (NP (NP (NP (NP (NP (CD 197.5)) (PRN (-LRB- -LRB-) (NP (CD 151.8) (: ;) (CD 249.2)) (-RRB- -RRB-))) (TO to) (NP (CD 66.1))) (PRN (-LRB- -LRB-) (NP (CD 41.2) (: ;) (CD 136.5)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (PRN (-LRB- -LRB-) (NP (NP (NN 25th)) (: ;) (NP (NN 75th) (NN percentile))) (-RRB- -RRB-))) (-RRB- -RRB-))) (NN pmol/l)))) (: ;)))
(S1 (S (NP (NP (NN p) (NN &amp)) (: ;) (NP (NN lt)) (: ;))))
(S1 (S (NP (NP (CD 0.001)) (. .))))
(S1 (S (S (NP (NN drug1) (NN dose)) (VP (VBD increased) (PP (IN from) (NP (CD 30.0) (QP (CD 6) (TO to) (CD 63)) (ADJP (CD 25) (NN mg/day)) (, ,) (NN p) (NN &lt))))) (: ;)))
(S1 (S (NP (NP (CD 0.05)) (. .))))
(S1 (S (S (NP (NN Hemoglobin)) (VP (VBD remained) (ADJP (ADJP (JJ unchanged)) (PRN (-LRB- -LRB-) (ADJP (QP (CD 116)) (QP (CD 13) (TO to) (CD 116)) (CD 13) (NN g/l)) (-RRB- -RRB-))) (, ,) (SBAR (IN while) (S (NP (NN drug1) (NN requirement)) (VP (VBD decreased) (PP (IN from) (NP (CD 40) (-LRB- -LRB-) (CD 20) (: ;) (CD 60) (-RRB- -RRB-))) (PP (TO to) (NP (NP (QP (QP (CD 24)) (PRN (-LRB- -LRB-) (NP (CD 19) (: ;) (CD 59)) (-RRB- -RRB-))) (NN g/week)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD 0.02))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN remainder)) (PP (IN of) (NP (NP (NP (DT the) (JJ dialysis-related) (NN biochemistry)) (PRN (-LRB- -LRB-) (NP (NP (NNS electrolytes)) (, ,) (NP (NN calcium)) (, ,) (NP (NN phosphate)) (, ,) (NP (NN iron) (NN status))) (-RRB- -RRB-))) (CC and) (NP (NN vitamin) (NN D) (NN use))))) (VP (VBD remained) (ADJP (JJ unchanged)))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN reduction)) (PP (IN in) (NP (NP (NN PTH) (NN level)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 30)) (NN %)))))) (VP (VBD was) (VP (VBN experienced) (PP (IN by) (NP (NP (NP (CD 82.5) (NN %)) (PRN (-LRB- -LRB-) (NP (NN 33/40)) (-RRB- -RRB-))) (PP (IN of) (NP (PRP$ our) (NN cohort)))))))) (. .)))
(S1 (S (PP (IN Among) (NP (DT the) (NNS responders))) (, ,) (NP (NP (DT the)) (VP (VBP fall) (PP (IN in) (NP (NP (NN PTH)) (CC and) (NP (NN reduction)) (NP (NN drug1) (NN requirement)))))) (VP (VBD were) (VP (JJ related) (PRN (-LRB- -LRB-) (NP (NP (NN R)) (ADJP (JJ =) (NP (CD -0.48)))) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.004)))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NN Reduction)) (PP (IN of) (NP (NN PTH))) (PP (IN by) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN drug2) (NN requirement)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interface)) (PP (IN between) (NP (NN bone) (CC and) (NN bone) (NN marrow))) (PP (IN in) (NP (NN uremia)))) (VP (VBZ represents) (NP (NP (DT a) (JJ critical) (NN step)) (PP (IN in) (NP (JJ red) (NN blood) (NN cell) (NN production))) (SBAR (WHNP (WDT which)) (S (VP (NNS merits) (NP (JJ further) (NN investigation)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (CD 5) (NNS milligrams)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))) (PP (IN at) (NP (NP (NNS doses)) (ADJP (JJR less) (PP (IN than) (NP (NP (CD 800) (NNS milligrams)) (PP (IN in) (NP (JJ nonpregnant) (NNS women)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT the) (ADJP (RB only) (JJ known)) (NN component)) (PP (IN in) (NP (DT the) (NN diet))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NP (NN absorption)) (PP (IN of) (NP (CC both) (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN evidence)) (PP (IN for) (NP (NP (DT a) (JJ drug1) (NN effect)) (PP (IN on) (NP (NN drug2) (NN absorption)))))) (ADVP (RB mainly)) (VP (VBZ comes) (PP (IN from) (NP (NP (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD did) (RB not) (VP (VB isolate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3)))) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (JJ other) (JJ dietary) (NNS components))))) (, ,) (SBAR (IN because) (S (NP (PRP it)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (JJ single-meal) (NNS studies))))))))))))))) (. .)))
(S1 (S (NP (PRP$ Our) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB establish) (NP (NP (JJ potential) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (NN absorption)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (CC and) (NP (NP (DT the) (NN dose) (NN response)) (PP (IN for) (NP (DT this) (NN effect))))))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT a) (NN meal))))))))) (. .)))
(S1 (S (S (NP (JJ Fifty-four) (ADJP (ADJP (JJ healthy)) (, ,) (ADJP (JJ nonpregnant))) (NNS women)) (VP (VBD were) (VP (VBN selected) (S (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (CD 4) (JJ drug1) (NN absorption) (NNS studies)) (VP (VBG using) (NP (NN iron) (JJ radioactive) (NNS tracers))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ drug1) (NNS doses)) (PP (IN between) (NP (QP (CD 200) (CC and) (CD 1500)) (NN mg))))) (PP (IN on) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (ADJP (CD 5) (NN mg)) (NN drug2)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NN drug3))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ drug1) (NNS doses)) (PP (IN between) (NP (QP (CD 200) (CC and) (CD 800)) (NN mg))))) (PP (IN on) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (ADJP (CD 5) (NN mg)) (NN drug2) (NN -LSB-as) (JJ concentrated) (NNS RBC)) (PRN (-LRB- -LRB-) (NP (NN CRBC)) (-RRB- -RRB-)))))) (-RRB- -RSB-))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN as) (NP (NN drug2))) (PP (IN in) (NP (DT all) (NNS studies)))))) (CC and) (S (NP (NN drug3)) (VP (VBD were) (VP (VBN ingested) (PP (IN on) (NP (DT an) (JJ empty) (NN stomach))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS doses)) (NP (CD 1000) (NN mg))) (VP (VBD diminished) (NP (NN drug2) (NN absorption)) (PP (IN by) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 49.6) (NN %))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ drug1) (NN dose)) (PP (IN of) (NP (CD 800) (NN mg)))) (VP (VBD diminished) (NP (NP (NN absorption)) (PP (IN of) (NP (ADJP (CD 5) (NN mg)) (NN drug2))) (PP (IN by) (NP (CD 37.7) (NN %)))))) (. .)))
(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (NP (NP (DT an) (VBN isolated) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NN chloride))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (CD 5) (NN mg)) (PP (IN of) (NP (NP (NN iron)) (VP (VBN provided) (PP (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NN sulfate))) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NN CRBC))) (-RRB- -RRB-))) (NP (NN drug3))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBD was) (VP (VBN observed) (PP (IN at) (NP (NP (NNS doses)) (ADJP (ADJP (JJR higher)) (SBAR (IN than) (S (ADVP (RB previously)) (VP (VBN reported) (PP (IN from) (NP (JJ single-meal) (NNS studies))))))))) (, ,) (S (VP (VBG starting) (PP (IN at) (NP (NP (CD ~800) (NN mg)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Synergistic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (ADJP (NN sequence) (JJ dependent)) (PP (IN in) (NP (NP (JJ human) (NN non-small) (NN lung) (NN cancer)) (PP (IN with) (NP (NN EGFR) (JJ TKIs-resistant) (NN mutation))))))) (. .)))
(S1 (S (S (NP (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ has) (NP (NP (DT the) (JJ anti-tumor) (NN activity)) (PP (IN in) (NP (NP (JJ human) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD was) (VP (VBN aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (JJ single) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NP (DT that)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ concurrent)) (CC or) (ADJP (JJ sequential))) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))) (PP (IN in) (NP (NP (NN NSCLC) (NN cell) (NNS lines)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ resistant) (PP (TO to) (NP (NN EGFR) (NN TKIs)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN NSCLC) (NN cell) (NNS lines)) (PP (IN with) (NP (NP (NN EGFR) (NN T790M) (NN mutation)) (CC and) (NP (NN K-ras) (NN mutation))))) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (CC either) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (CC or) (NP (NP (DT both)) (VP (VBN based) (PP (IN on) (NP (JJ various) (JJ sequential) (NNS administrations)))))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NN exposure))) (, ,) (S (NP (DT the) (NN cell) (NN viability)) (VP (VBD was) (VP (VBN measured) (PP (IN by) (NP (NN MTT) (NN assay)))))) (, ,) (S (NP (NN cell) (NN cycle) (NN distribution)) (VP (VBD was) (VP (VBN analyzed) (PP (IN by) (NP (NN flow) (NN cytometry)))))) (, ,) (CC and) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NN signaling) (NN pathway)))) (VP (VBD were) (VP (VBN determined) (PP (IN by) (NP (NN immunoblotting))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VP (VBD exhibited) (NP (JJ dose-dependent) (NN growth) (NN inhibition)) (PP (IN in) (NP (NN NSCLC) (NN cell) (NNS lines)))) (CC and) (VP (VBD arrested) (NP (NN cell) (NN cycle)) (PP (IN at) (NP (NN G1) (NN phase)))))) (, ,) (IN whereas) (S (NP (NN drug2)) (VP (VBD arrested) (PP (IN at) (NP (NN S) (NN phase)))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (ADJP (ADJP (JJ single)) (CC or) (ADJP (JJ concurrent))) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (NP (DT some) (JJ anti-proliferative) (NNS effects))))) (, ,) (NP (NP (DT the) (JJ sequential) (NNS administrations)) (PP (IN of) (NP (DT both) (NNS drugs)))) (ADVP (RB remarkably)) (VP (VBD enhanced) (NP (JJ anti-tumor) (NN activity)))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NNS cells)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NN drug1))) (S (VP (VBN followed) (PP (IN by) (NP (NN drug2))))))))) (, ,) (NP (NN synergism)) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ molecular) (NN basis)) (PP (IN of) (NP (DT this) (NN synergism)))) (VP (VBZ is) (SBAR (IN that) (S (NP (NP (DT the) (NN signaling) (NNS pathways)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (ADVP (RB initially)) (VP (VBN activated) (PP (IN by) (NP (NN drug1) (NN exposure)))))))) (VP (VBD were) (ADVP (RB efficiently)) (VP (VBN suppressed) (PP (IN by) (NP (NP (DT the) (JJ subsequent) (NN exposure)) (PP (TO to) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN reverse)) (PP (IN of) (NP (DT this) (JJ sequential) (NN administration)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN antagonism)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ differential) (NNS effects)) (PP (IN on) (NP (NN cell) (NN cycle) (NN arrest)))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (PP (IN as) (NP (DT a) (JJ single) (NN agent)))) (VP (VBZ exhibits) (NP (JJ anti-proliferative) (NNS effects)) (ADVP (FW in) (FW vitro)) (PP (IN in) (NP (NP (NN NSCLC) (NN cell) (NNS lines)) (PP (IN with) (NP (NN EGFR) (NN T790M) (CC and) (NN K-ras) (NNS mutations))))))) (CC but) (S (NP (NP (DT the) (JJ sequential) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (VP (VBN followed) (PP (IN by) (NP (NN drug3))))))) (VP (VBZ is) (ADJP (JJ superior) (PP (TO to) (NP (NP (NN drug4)) (VP (VBN followed) (PP (IN by) (NP (NP (NN drug5)) (CC and) (NP (JJ concurrent) (NN administration))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Determinants)) (PP (IN of) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NN drug1)))))) (VP (VBD induced) (NP (NN apoptosis)) (PP (IN in) (NP (JJ multiple) (NN myeloma) (NNS cells))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (NP (NN S-adenosylhomocysteine)) (PRN (-LRB- -LRB-) (NP (NN AdoHcy)) (-RRB- -RRB-))) (NN hydrolase) (NNS inhibitors)))) (, ,)) (VP (VBZ has) (VP (VBN shown) (NP (JJ antitumor) (NNS activities)) (PP (IN in) (NP (NP (DT a) (JJ broad) (NN range)) (PP (IN of) (NP (NP (JJ solid) (NNS tumors)) (CC and) (NP (JJ acute) (JJ myeloid) (NN leukemia))))))))) (. .)))
(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VP (VBD examined) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NP (NP (JJ multiple) (NN myeloma)) (PRN (-LRB- -LRB-) (NP (NN MM)) (-RRB- -RRB-))) (NNS cells))))) (CC and) (VP (VBD found) (SBAR (IN that) (S (, ,) (PP (IN at) (NP (CD 500) (NN nM))) (, ,) (NP (PRP it)) (ADVP (RB potently)) (VP (VP (VBD inhibited) (NP (NN growth))) (CC and) (VP (VBD induced) (NP (NP (NN apoptosis)) (PP (IN in) (NP (QP (CD 2) (IN of) (CD 8)) (NN MM) (NN cell) (NNS lines)))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN RNA)) (PP (IN from) (NP (ADJP (ADJP (JJ un-treated)) (CC and) (ADJP (JJ drug1))) (JJ treated) (NNS cells)))) (VP (VBD was) (VP (VBN profiled) (PP (IN by) (NP (NN Affymetrix) (NN HG-U133) (NN Plus) (CD 2.0) (NN microarray)))))) (CC and) (S (NP (NP (NNS genes)) (PP (IN with) (NP (NP (DT a) (JJ significant) (NN change)) (PP (IN in) (NP (NN gene) (NN expression)))))) (VP (VBD were) (VP (VBN determined) (PP (IN by) (NP (NP (NN significance) (NN analysis)) (PP (IN of) (NP (NN microarray) (-LRB- -LRB-) (NN SAM) (-RRB- -RRB-) (NN testing))))))))) (. .)))
(S1 (S (S (NP (NN ALOX5)) (VP (VP (VBD was) (NP (DT the) (ADJP (RBS most) (VBN down-regulated)) (NN gene)) (PRN (-LRB- -LRB-) (ADVP (RB 5.8-fold)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ sensitive) (NNS cells)))) (CC and) (VP (VBD was) (VP (VBN expressed) (PP (IN at) (NP (JJ low) (NN level))) (PP (IN in) (NP (JJ resistant) (NNS cells))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD were) (VP (VBN corroborated) (PP (IN by) (NP (JJ quantitative) (NN RT-PCR)))))) (. .)))
(S1 (S (S (NP (JJ Western-blot) (NN analysis)) (VP (VBD indicated) (NP (NN ALOX5)) (VP (VP (VBD was) (ADVP (RB highly)) (VP (VBN expressed) (ADVP (RB only)) (PP (IN in) (NP (JJ sensitive) (NN cell) (NN line) (CD H929))))) (CC and) (ADVP (RB greatly)) (VP (VBD decreased) (PP (IN upon) (NP (NN drug1) (NN treatment))))))) (. .)))
(S1 (S (S (NP (NP (JJ Ectopic) (NN expression)) (PP (IN of) (NP (NN ALOX5)))) (VP (VBD reduced) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NN drug1)))) (PP (IN in) (NP (NN H929) (NNS cells))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NN ALOX5))) (PP (IN by) (NP (NN RNA) (NN interference)))) (VP (MD could) (ADVP (RB also)) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (NN H929)))))) (. .)))
(S1 (S (S (NP (NP (NN Gene) (NN expression) (NN analysis)) (PP (IN on) (NP (NN MM) (NN patient) (NN dataset)))) (VP (VBD indicated) (NP (NN ALOX5) (NN expression)) (VP (VBD was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN MM) (NNS patients))) (PP (VBN compared) (PP (TO to) (NP (JJ normal) (NN plasma) (NNS cells))))))) (. .)))
(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (IN that) (S (S (NP (NN Bcl-2)) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN drug1) (JJ insensitive) (NNS cells)))))) (, ,) (CC and) (S (NP (NP (NN cotreatment)) (PP (IN with) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (, ,) (NP (DT a) (NN Bcl-2) (NN family) (NN inhibitor)) (, ,)))) (ADVP (RB synergistically)) (VP (VP (VBD inhibited) (NP (NN growth))) (CC and) (VP (VBD induced) (NP (NP (NN apoptosis)) (PP (IN of) (NP (NN drug4) (JJ insensitive) (NN MM) (NNS cells)))))))))) (. .)))
(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT this) (NN study)) (VP (VBZ shows) (NP (NP (CD one)) (PP (IN of) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (DT the) (NN drug1) (NN efficacy)))))) (PP (IN on) (NP (NP (JJ MM) (NNS correlates)) (PP (IN with) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB down-regulate) (NP (DT the) (NN ALOX5) (NNS levels)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (S (NP (NN drug1) (NN insensitivity)) (VP (MD might) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN overexpression)) (PP (IN of) (NP (NN Bcl-2))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD could) (ADVP (RB synergistically)) (VP (VBD induced) (NP (NN apoptosis)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN exploited) (ADVP (RB therapeutically)) (PP (IN for) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NN MM)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN infant) (NN colic) (NN drops))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Forest)) (NP (NNS Laboratories))) (NP (NNP UK) (, ,) (NNP Kent) (, ,) (NNP UK))) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB widely) (JJ available)) (NN over-the-counter) (NN preparation)) (VP (VBN used) (S (VP (TO to) (VP (VBP relieve) (NP (NP (NN colic) (NNS symptoms)) (PP (IN in) (NP (NP (NNS neonates)) (CC and) (NP (NNS infants)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ active) (NN ingredient)) (VP (VBZ is) (NP (NN drug1)))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (VP (VBP are) (VP (VBN documented) (PP (IN in) (NP (NP (DT the) (JJ current) (NN summary)) (PP (IN of) (NP (NN product) (NNS characteristics)))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS authors)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT an) (NN infant)) (PP (IN with) (NP (VBN confirmed) (JJ congenital) (NN hypothyroidism))) (PP (IN on) (NP (NP (NN drug1)) (SBAR (WHNP (WP who)) (S (VP (VBN experienced) (NP (NP (DT a) (JJ possible) (NN drug) (NN interaction)) (PP (IN with) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (PP (IN Despite) (NP (JJ adequate) (NN drug1) (NN dosage))) (, ,) (NP (NP (NN thyroid) (NN stimulating) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN TSH)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJ high)) (, ,) (S (VP (VBG suggesting) (NP (NN undertreatment)))))) (. .)))
(S1 (S (S (NP (NN Questioning)) (VP (VBD revealed) (NP (NP (DT the) (NN child)) (VP (VBD was) (PP (VBG taking) (NP (NN drug1) (NN drops))) (SBAR (IN before) (S (VP (VBZ feeds) (PP (IN while) (PP (IN on) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (S (NP (DT The) (NN colic) (NN drops)) (VP (VBD were) (ADVP (RB immediately)) (VP (VBN discontinued)))) (CC and) (S (NP (NN TSH)) (ADVP (RB promptly)) (VP (VBD normalised) (PP (IN with) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN thyroxine)) (NN requirement))) (PP (TO to) (NP (DT an) (NN age) (JJ appropriate) (NN dosage)))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (ADVP (RB previously))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN listed) (PP (IN in) (NP (NP (DT the) (NNP British) (NNP National) (NN Formulary)) (PP (IN for) (NP (NNS Children))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Clinicians)) (CC and) (NP (NNS parents))) (VP (VBP need) (S (VP (TO to) (VP (VB be) (NP (NP (NN aware)) (PP (IN of) (NP (DT this) (NN interaction))) (S (VP (TO to) (VP (VP (VB avoid) (NP (JJ unnecessary) (NN undertreatment))) (CC and) (VP (VB prevent) (NP (JJ potential) (JJ long-term) (JJ neurological) (NN sequelae)))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ drug1) (NN locomotor) (NN sensitization)) (CC and) (NP (JJ conditioned) (NN place) (NN preference))) (PP (IN in) (NP (JJ adolescent) (ADJP (ADJP (JJ male)) (CC and) (ADJP (JJ female))) (NNS rats)))) (ADVP (RB neonatally)) (VP (VBN treated) (PP (IN with) (NP (NN drug2))))) (. .)))
(S1 (S (S (NP (JJ Neonatal) (NN drug1) (NN treatment)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB produce) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN dopamine) (JJ D2-like) (NN receptor)) (NN sensitivity))) (SBAR (WHNP (WDT that)) (S (VP (VBZ persists) (PP (IN throughout) (NP (NP (DT the) (NN subject) (POS 's)) (NN lifetime)))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ neonatal) (NN drug1) (NN treatment))) (PP (IN on) (NP (NP (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (JJ adolescent) (NNS rats)) (VP (VBG using) (NP (NP (NP (NN locomotor) (NN sensitization)) (CC and) (NP (JJ conditioned) (NN place) (NN preference))) (NNS procedures))))))))))))) (. .)))
(S1 (S (S (NP (NN Sprague-Dawley) (NNS rats)) (VP (VBD were) (VP (VP (VBN treated) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NN saline)))) (PP (IN from) (NP (NP (NP (JJ postnatal) (NNS days)) (PRN (-LRB- -LRB-) (NP (NN P)) (-RRB- -RRB-))) (QP (CD 1) (TO to) (CD P11))))) (CC and) (VP (VBN raised) (PP (TO to) (NP (NN adolescence))))))) (. .)))
(S1 (S (PP (IN For) (NP (NN locomotor) (NN sensitization))) (, ,) (NP (NNS subjects)) (VP (VP (VBD were) (VP (VBN given) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NN saline)) (NP (DT every) (JJ second) (NN day))) (PP (IN from) (NP (NN P35))) (PP (TO to) (NP (NN P47))))) (CC and) (VP (VBD were) (VP (VBN placed) (PP (IN into) (NP (DT a) (JJ locomotor) (NN arena)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (JJ neonatal) (NN drug1) (NN treatment)) (VP (VBD enhanced) (NP (NN drug2) (NN locomotor) (NN sensitization)) (PP (VBN compared) (PP (IN with) (NP (NP (CD drug3) (JJ -free) (NNS controls)) (VP (VBN sensitized) (PP (TO to) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (JJ Male) (NNS rats)) (VP (VBD demonstrated) (NP (NP (NN sensitization)) (PP (TO to) (NP (NN drug1)))) (, ,) (SBAR (IN although) (S (NP (DT this)) (VP (VP (VBD was) (VP (VBN muted) (PP (VBN compared) (PP (IN with) (NP (JJ female) (NNS rats)))))) (, ,) (CC and) (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (JJ neonatal) (NN drug2)))))))))) (. .)))
(S1 (S (S (S (PP (IN For) (NP (JJ conditioned) (NN place) (NN preference))) (, ,) (NP (NNS subjects)) (VP (VBD were) (VP (VBN conditioned) (PP (IN for) (NP (NP (NP (CD 8) (JJ consecutive) (NNS days)) (PRN (-LRB- -LRB-) (NP (NN P32-39)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NN saline))))))))) (CC and) (S (NP (DT a) (JJ drug-free) (NN preference) (NN test)) (VP (VBD was) (VP (VBN conducted) (PP (IN at) (NP (NN P40))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ neonatal) (JJ drug1) (VBN enhanced) (NN time) (NN spent)) (PP (IN in) (NP (DT the) (JJ drug2) (JJ -paired) (NN context))))) (PP (VBN compared) (PP (IN with) (NP (NP (CD drug3) (JJ -free) (NNS controls)) (VP (VBN conditioned) (PP (IN with) (NP (NN drug4))))))))) (, ,) (CONJP (CC but) (RB only)) (NP (JJ female) (NNS controls))) (VP (VBN conditioned) (PP (IN with) (NP (NN drug5))))) (VP (VBP spent) (NP (JJR more) (NN time)) (PP (IN in) (NP (DT the) (JJ drug-paired) (NN context))) (PP (VBN compared) (PP (IN with) (NP (JJ saline-treated) (NNS controls))))) (. .)))
(S1 (S (S (S (NP (VBN Increased) (NP (NN D) (JJ -like) (NN receptor)) (NN sensitivity)) (VP (VBZ appears) (S (VP (TO to) (VP (VB have) (VP (VBD enhanced) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NN drug1)))))))))) (, ,) (CC but) (S (NP (DT these) (NNS effects)) (VP (VBD were) (ADJP (RBR more) (JJ prevalent)) (PP (IN in) (NP (JJ adolescent) (JJ female) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (JJ male) (NNS rats))))))) (. .)))
(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NN drug1) (JJ -mediated) (NN CYP3A4) (NN inhibition))) (PP (IN on) (NP (NP (JJ clinical) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (DT an) (ADJP (RB orally) (JJ active)) (NN drug4)))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB partly)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))) (ADVP (FW in) (FW vitro))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD evaluated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ potent) (NN CYP3A) (NN inhibitor)) (, ,) (NP (NN drug1)) (, ,))) (PP (IN on) (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (DT a) (JJ single) (NN drug1) (JJ oral) (NN dose)) (PP (IN on) (NP (NN day) (CD 1))) (, ,) (VP (VBN followed) (PP (IN by) (NP (CD 4) (NNS days) (NN wash-out) (NN period))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NNS days) (NP (CD 5-9)))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN administered)))) (. .)))
(S1 (S (S (PP (IN On) (NP (NN day) (CD 8))) (, ,) (NP (DT a) (JJ single) (NN drug1) (NN dose)) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (IN as) (NP (NP (JJ single) (NN agent)) (NP (NP (CD three) (NNS times)) (NP (NP (DT a) (NN week)) (PP (IN on) (NP (NN day) (CD 15) (CC and) (CD onward)))))))))) (. .)))
(S1 (S (S (PP (IN In) (DT the) (NN presence) (IN of) (NP (NN drug1))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (NN 1.6-)) (CC and) (NP (NP (JJ 1.8-fold) (NN increase)) (PP (IN in) (NP (NP (NP (NN C)) (PRN (-LRB- -LRB-) (NP (NN max)) (-RRB- -RRB-))) (CC and) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug2))))))) (, ,) (ADVP (RB respectively))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ substantial) (NN change)) (PP (IN in) (NP (NP (NP (NN T)) (PRN (-LRB- -LRB-) (NP (NN max)) (-RRB- -RRB-))) (CC or) (NP (NN half-life))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN difference)) (PP (IN in) (NP (NN drug1) (NNS -pharmacokinetics))) (PP (IN between) (NP (NP (NNS patients)) (VP (VBG carrying) (NP (NP (NP (NN CYP3A5) (NN *) (NN 1/) (NN *) (CD 3)) (CC and) (NP (NN CYP3A5) (NN *) (NN 3/) (NN *) (CD 3))) (NNS alleles)))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (ADJP (ADVP (RBS Most) (RB frequently)) (VBN reported)) (JJ adverse) (NNS events)) (VP (VBD were) (ADJP (JJ gastrointestinal) (JJ related)))) (. .)))
(S1 (S (S (S (NP (NNS Patients)) (VP (VBD had) (NP (NP (JJ asymptomatic) (NN hypophosphatemia)) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NN urine) (NN analysis)) (VP (VBD suggested) (NP (JJ renal) (NN phosphate) (NN wasting))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN CYP3A) (NNS inhibitors)))) (VP (VBZ is) (ADJP (JJ feasible)) (SBAR (IN as) (S (NP (NP (DT the) (VBN observed) (NN increase)) (PP (IN in) (NP (NN drug2) (NN PK) (NNS parameters)))) (VP (VBD was) (RB not) (VP (VBD considered) (ADJP (RB clinically) (JJ relevant)))))))) (. .)))
(S1 (S (S (S (VP (VBG Considering) (NP (NP (DT the) (NN variability)) (PP (IN in) (NP (NP (NN exposure)) (PP (VBG following) (NP (NP (NN enzyme) (NN inhibition)) (CC and) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (JJ chronic) (NN dosing)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (RB not) (VP (VBN studied) (PP (IN with) (NP (NN CYP3A) (NNS inhibitors))))))))))))))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (ADJP (NN drug2) (JJ -related)) (JJ adverse) (NNS events)))) (VP (VBZ is) (ADJP (JJ necessary)))) (. .)))
(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN CYP) (NNS inhibitors))) (PP (IN on) (NP (NP (NP (NN drug1) (NN metabolism)) (CC and) (NP (NN toxicity))) (PP (IN in) (NP (NN rat) (NN liver) (NNS slices))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ comprehensive) (ADJP (FW in) (FW vitro)) (NN approach)) (PP (TO to) (S (VP (VBG assessing) (NP (NP (JJ metabolism-mediated) (NN hepatotoxicity)) (VP (VBG using) (NP (NP (JJ male) (NN Sprague-Dawley) (NN rat) (NN liver) (NNS slices)) (VP (VBN incubated) (PP (IN with) (NP (NP (DT the) (ADJP (RB well) (VBN characterized)) (NN hepatotoxicant)) (, ,) (NP (NN drug1)) (, ,) (CC and) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NNS enzymes)))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN approach)) (VP (VBZ combines) (NP (NP (NP (JJ liquid) (NN chromatography) (NN mass) (NN spectrometry)) (PRN (-LRB- -LRB-) (NP (CD LC) (NN MS)) (-RRB- -RRB-))) (NN detection) (NNS methods)) (PP (IN with) (NP (JJ multiple) (NN toxicity) (NNS endpoints))) (S (VP (TO to) (VP (VB enable) (NP (NP (NN identification)) (PP (IN of) (NP (NP (JJ critical) (JJ metabolic) (NNS pathways)) (PP (IN for) (NP (NN hepatotoxicity))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS incubations)) (VP (VBD were) (VP (VBN performed) (PP (IN in) (NP (NP (DT the) (NP (NN absence)) (CC and) (NP (NN presence))) (PP (IN of) (NP (NP (DT the) (JJ non-specific) (NN CYP) (NN inhibitor)) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (JJ isoform-specific) (NNS inhibitors))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN metabolite) (NN profile)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NN rat) (NN liver) (NNS slices)))) (VP (VP (VBZ shares) (NP (NP (DT some) (NNS features)) (PP (IN of) (NP (DT the) (ADJP (FW in) (FW vivo)) (NN profile))))) (, ,) (CC but) (ADVP (RB also)) (VP (VBD had) (NP (NP (DT a) (JJ major) (NN difference)) (SBAR (WHPP (IN in) (WHNP (WDT that))) (S (NP (NN epoxide) (NN dihydrodiol) (NN hydrolysis) (NNS products)) (VP (VBD were) (RB not) (VP (VBN observed) (PP (TO to) (NP (DT a) (JJ measurable) (NN extent)))))))))) (. .)))
(S1 (S (S (PP (IN As) (NP (NP (NNS examples)) (PP (IN of) (NP (PRP$ our) (NN liver) (NN slice) (NN metabolite) (NN identification) (NN procedure))))) (, ,) (NP (NP (DT a) (JJ minor) (NN glutathione) (NN adduct)) (CC and) (NP (NP (ADJP (RB previously) (VBN unreported)) (ADJP (ADJP (JJ 7-O-desmethyl)) (CC and) (ADJP (JJ glucuronidated))) (NNS metabolites)) (PP (IN of) (NP (NN drug1))))) (VP (VBP are) (VP (VBN reported)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD induced) (NP (JJ hepatocellular) (NN necrosis)) (PP (IN in) (NP (DT a) (ADJP (ADJP (NN dose-)) (CC and) (ADJP (JJ time-dependent))) (NN manner))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBD decreased) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug2))))) (, ,) (VP (VBD increased) (NP (NP (NN exposure)) (PP (TO to) (NP (NN parent) (NN compound))))) (, ,) (CC and) (VP (VBD decreased) (NP (NN metabolite) (NNS levels)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))) (. .)))
(S1 (S (PP (IN Of) (NP (NP (DT the) (JJ isoform-specific) (NN CYP) (NNS inhibitors)) (VP (VBN tested) (PP (IN for) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (DT the) (NN drug1) (NN metabolite) (NN profile)))))))) (, ,) (NP (RB only) (NN drug2)) (VP (VBD was) (ADVP (RB noticeably)) (ADJP (JJ effective)) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (NNS CYPs) (NP (NP (NN 2A6)) (, ,) (NP (NN 2C9)) (, ,) (NP (NN 2Cl9)) (, ,) (CC and) (NP (NN 2E1))))))))) (. .)))
(S1 (S (S (PP (IN With) (NN respect) (TO to) (NP (NN toxicity))) (, ,) (NP (NP (DT the) (NN order)) (PP (IN of) (NP (NN CYP) (NN inhibitor) (NN effectiveness)))) (VP (VBD was) (NP (NN drug1) (NN >) (NN drug2) (NN ~) (NN drug3) (NN >) (NN drug4)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD had) (NP (DT no) (NN effect)) (, ,) (SBAR (IN while) (S (NP (NN drug3)) (VP (VBD appeared) (S (VP (TO to) (VP (VB augment) (NP (NN drug4) (NN toxicity)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN rat) (NN liver) (NNS slices)) (VP (VP (VBP do) (RB not) (VP (VB reproduce) (NP (NP (DT the) (VBN reported) (ADJP (FW in) (FW vivo)) (NN biotransformation)) (PP (IN of) (NP (NN drug1)))))) (CC and) (VP (ADVP (RB therefore)) (VP (MD may) (RB not) (VP (VB be) (NP (NP (DT an) (JJ appropriate) (NN model)) (PP (IN for) (NP (NN drug2) (NN metabolism)))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS results)) (VP (VBP provide) (NP (NP (DT an) (NN example)) (PP (IN of) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ small) (NN molecule) (NN manipulation)) (PP (IN of) (NP (NN CYP) (NN activity))) (PP (IN in) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN model)))) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB confirm) (NP (JJ metabolism-mediated) (NN toxicity)))))))))))))) (. .)))
(S1 (S (S (NP (JJ Glycosidic) (NNS enzymes)) (VP (VBP enhance) (NP (NN retinal) (NN transduction)) (PP (VBG following) (NP (NP (JJ intravitreal) (NN delivery)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN co-injection)) (PP (IN of) (NP (JJ extracellular) (NN matrix) (NN degrading) (NNS enzymes)))) (VP (VBZ improves) (NP (NN retinal) (NN transduction)) (PP (VBG following) (NP (NP (JJ intravitreal) (NN delivery)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBG containing) (NP (NP (NN cDNA)) (VP (VBG encoding) (NP (NP (VBN enhanced) (JJ green) (JJ fluorescent) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN GFP)) (-RRB- -RRB-))) (, ,) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT a) (NN chicken) (NN -actin) (NN promoter))))) (, ,))))) (VP (VBD was) (VP (VBN delivered) (PP (IN by) (NP (NP (JJ intravitreal) (NN injection)) (PP (TO to) (NP (JJ adult) (NNS mice))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NNS enzymes)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5))))))))))))) (. .)))
(S1 (S (S (ADVP (NP (CD Two) (NNS weeks)) (RB later)) (, ,) (NP (JJ retinal) (NNS flatmounts)) (VP (VBD were) (VP (VBN examined) (PP (IN for) (NP (NP (NN GFP) (NN expression)) (VP (VBG using) (NP (JJ confocal) (NN microscopy)))))))) (. .)))
(S1 (S (S (PP (IN Without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNS enzymes))))) (, ,) (NP (NN transduction)) (VP (VBD was) (VP (VBN limited) (PP (TO to) (NP (NP (JJ occasional) (NNS cells)) (PP (IN in) (NP (DT the) (JJ retinal) (NN ganglion) (NN cell) (NN layer)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (ADVP (RB greatly)) (VP (VP (VBD enhanced) (NP (NP (NN transduction)) (PP (IN of) (NP (DT the) (JJ retinal) (NN ganglion) (NN cell) (NN layer))))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN depth)) (PP (IN of) (NP (NN transduction))) (PP (IN into) (NP (DT the) (JJ outer) (NN retina))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD had) (NP (DT a) (JJ limited) (NN effect)))) (CC and) (S (NP (NN drug2)) (VP (VBD was) (ADJP (JJ ineffective))))) (. .)))
(S1 (S (S (NP (NNS Electroretinograms)) (VP (VBD survived) (PP (IN with) (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (SBAR (IN than) (S (VP (VBD were) (VP (VBN required) (PP (IN for) (NP (JJ optimal) (JJ retinal) (NN transduction))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ -mediated) (NN retinal) (NN transduction)) (VP (VBZ is) (VP (VBN improved) (PP (IN by) (NP (NP (NN co-injection)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (JJ Improved) (NN transduction) (NN efficiency)) (VP (MD may) (VP (VB allow) (NP (JJ intravitreal) (NN injection)) (S (VP (TO to) (VP (VB become) (NP (NP (DT the) (JJ preferred) (NN route)) (PP (IN for) (S (VP (VBG delivering) (NP (NN gene) (NN therapy)) (PP (TO to) (NP (CC both) (DT the) (ADJP (ADJP (JJ inner)) (CC and) (ADJP (JJ outer))) (NNS retina))))))))))))) (. .)))
(S1 (S (NP (NP (ADJP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (JJ --better) (PP (IN than) (NP (NN drug3))))) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-)))))
(S1 (S (S (NP (DT The) (NN FDA)) (VP (VBZ has) (NP (NP (NP (JJ approved) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2) (NN -AstraZeneca)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ oral) (NN drug3)) (, ,)) (PP (IN for) (NP (NP (NN use)) (PP (IN with) (NP (JJ low-dose) (NN drug4))) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ thrombotic) (JJ cardiovascular) (NNS events)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (JJ coronary) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN ACS)) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD will) (VP (VB compete) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))) (PP (IN for) (NP (JJ such) (NN use)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB become) (ADJP (JJ available) (ADVP (RB generically))) (PP (IN in) (NP (DT the) (NP (PRP US)))) (PP (IN within) (NP (DT the) (JJ next) (JJ few) (NNS months))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ drug1) (JJ -enhanced) (NN drug2) (NN cytotoxicity)) (PP (IN in) (NP (JJ human) (JJ ovarian) (NN cancer) (NNS cells))))) (. .))))
(S1 (S (S (NP (NP (QP (JJR Less) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (JJ ovarian) (NNS cancers)))) (VP (VBP respond) (PP (TO to) (NP (NN drug1))))) (. .)))
(S1 (S (S (NP (JJ Effective) (NNS strategies)) (VP (VBP are) (VP (VBN needed) (S (VP (TO to) (VP (VB enhance) (NP (NN drug1) (NN sensitivity)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN library)) (PP (IN of) (NP (NP (JJ silencing) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS siRNAs)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (NNS kinases)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NN drug1) (NN sensitivity)) (PP (IN in) (NP (JJ human) (JJ ovarian) (NN cancer) (JJ SKOv3) (NNS cells))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (NN Src)) (CC and) (NP (NN Abl) (NNS kinases))))) (, ,))) (PP (IN on) (NP (NN drug2) (NN sensitivity)))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (JJ ovarian) (NN cancer) (NNS cells)) (CC and) (NP (NN HEY) (NNS xenografts))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS roles)) (PP (IN of) (NP (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (, ,) (NP (NN Bcl-2)) (, ,) (CC and) (NP (NN Cdk1)))) (PP (IN in) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (VP (VBD were) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (NP (NP (DT a) (JJ terminal) (NN deoxynucleotidyl) (JJ transferase-mediated) (NN dUTP) (NN nick-end) (NN labeling)) (PRN (-LRB- -LRB-) (NP (NN TUNEL)) (-RRB- -RRB-))) (NN assay)) (, ,) (NP (NP (NN siRNA) (NN knockdown)) (PP (IN of) (NP (NN gene) (NN expression)))) (, ,) (NP (NP (NN transfection)) (PP (IN with) (NP (NP (NN Bcl-2)) (CC and) (NP (NN Cdk1) (NN expression) (NNS vectors))))) (, ,) (CC and) (NP (NN flow) (NN cytometry)))))))) (. .)))
(S1 (S (S (NP (DT All) (JJ statistical) (NNS tests)) (VP (VBD were) (VP (VBN two-sided)))) (. .)))
(S1 (S (S (NP (NN Src) (NN family) (CC and) (NN Abl) (NNS kinases)) (VP (VBD were) (VP (VBN identified) (PP (IN as) (NP (NP (NNS modulators)) (PP (IN of) (NP (NN drug1) (NN sensitivity))) (PP (IN in) (NP (JJ SKOv3) (NNS cells)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN siRNA) (NN knockdown)) (PP (IN of) (NP (NP (NN Src)) (, ,) (NP (NN Fyn)) (, ,) (CC or) (NP (NN Abl1))))) (VP (VBD enhanced) (NP (ADJP (NN drug1) (JJ -mediated)) (NN growth) (NN inhibition)) (PP (IN in) (NP (JJ ovarian) (NN cancer) (NNS cells))) (PP (VBN compared) (PP (IN with) (NP (DT a) (NN control) (NN siRNA)))))) (. .)))
(S1 (S (S (NP (NP (NN HEY) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC plus) (NP (NN drug2)))))) (VP (VBD formed) (NP (JJR fewer) (NNS colonies)) (SBAR (IN than) (SINV (VBD did) (NP (NP (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (DT either) (NN agent)) (ADVP (RB alone)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NN HEY) (JJ xenograft-bearing) (NNS mice))) (PP (IN with) (NP (NP (NN drug1)) (CC plus) (NP (NN drug2))))) (VP (VBD inhibited) (NP (NP (NN tumor) (NN growth)) (ADJP (JJR more) (PP (IN than) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (DT either) (NN agent)) (ADVP (RB alone)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (JJ average) (NN tumor) (NN volume)) (PP (IN per) (NP (NP (NN mouse)) (, ,) (NP (NN drug3)) (CC +) (NP (NN drug4))))) (CC vs) (NP (NN drug5))) (PRN (: :) (NP (CD 0.28) (CC vs.) (CD 0.81) (NN cm3) (, ,) (NN difference) (JJ =) (CD 0.53) (NN cm3)) (, ,) (NP (CD 95) (NN %) (NN confidence) (NN interval) (NN -LSB-CI)) (-RRB- -RSB-))) (ADJP (JJ =) (NP (QP (CD 0.44) (TO to) (CD 0.62)) (NN cm3)))) (, ,) (NP (NN P) (JJ =) (CD .014)) (-RRB- -RRB-)))) (: ;)))
(S1 (S (S (NP (NP (NN drug1)) (CC +) (NP (NN drug2))) (NP (CC vs))) (. .)))
(S1 (S (S (NP (NN drug1)) (: :) (NP (QP (CD 0.28)) (CC vs))) (. .)))
(S1 (S (S (NP (CD 0.55) (NN cm3)) (, ,) (NP (NN difference)) (VP (JJ =) (NP (CD 0.27) (NP (CD cm3)) (PRN (, ,) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (ADJP (JJ =) (NP (QP (CD 0.21) (TO to) (CD 0.33)) (NN cm3)))) (, ,) (S (NP (NN P)) (VP (JJ =) (NP (CD .035)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (JJ Combined) (NN treatment)) (VP (VBD induced) (NP (ADJP (RBR more) (JJ TUNEL-positive)) (JJ apoptotic) (NNS cells)) (SBAR (IN than) (SINV (VBD did) (NP (NP (DT either) (NN agent)) (ADVP (RB alone))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN siRNA) (NN knockdown)) (PP (IN of) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))))) (VP (VBD decreased) (NP (NP (NN drug1)) (: -) (CC and) (NP (ADJP (NN drug2) (JJ -induced)) (NN apoptosis))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (JJ negative) (NN control) (NN siRNA)) (PRN (-LRB- -LRB-) (NP (NP (NN sub-G1) (NN fraction)) (, ,) (NP (NN control) (NN siRNA)) (CC vs.) (NP (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN siRNA))) (: :) (NP (NP (CD 42.5) (NN %)) (CC vs.) (NP (CD 20.1) (NN %))) (, ,) (NP (NN difference) (JJ =) (CD 22.4) (NN %) (, ,) (CD 95) (NN %) (NN CI) (JJ =) (CD 20.1) (NN %) (TO to) (CD 24.7) (NN %)) (, ,) (NP (NN P) (JJ =) (NN .017)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (NP (NP (VBN forced) (NN expression)) (CC and) (NP (NN siRNA) (NN knockdown))) (PP (IN of) (NP (NP (NN Bcl-2)) (CC and) (NP (NN Cdk1))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN drug1) (JJ -mediated) (NN induction)) (PP (IN of) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))))) (VP (VBD enhanced) (NP (NN drug2) (JJ -induced) (NN apoptosis)) (PP (IN by) (S (VP (ADVP (RB negatively)) (VBG regulating) (NP (NN Bcl-2) (CC and) (NN Cdk1) (NN expression)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NN Src) (NN family)) (CC and) (NP (NN Abl) (NNS kinases)))) (PP (IN with) (NP (CC either) (NP (NN siRNAs)) (CC or) (NP (NN drug1))))) (VP (VBZ enhances) (NP (NP (NN drug2) (NN sensitivity)) (PP (IN of) (NP (JJ ovarian) (NN cancer) (NNS cells)))) (PP (IN through) (NP (NP (ADJP (NN p27) (-LRB- -LRB-) (NN Kip1) (-RRB- -RRB-) (JJ -mediated)) (NN suppression)) (PP (IN of) (NP (NP (NN Bcl-2)) (CC and) (NP (NN Cdk1) (NN expression)))))))) (. .)))
(S1 (S (S (NP (NP (NN Influence)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NN drug2)))) (VP (VBD induced) (NP (NP (NN antinociception)) (CC and) (NP (PRP$ its) (NNS pharmacokinetics))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN CAS) (NN 94-62-2)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN alkaloid)) (VP (VBN obtained) (PP (IN from) (NP (NP (NN Piper) (NN nigrum)) (CC and) (NP (NN P))))))) (. .)))
(S1 (S (S (NP (NP (FW longum)) (, ,)) (VP (VBZ is) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NP (NP (JJ various) (NNS enzymes)) (PRN (-LRB- -LRB-) (NP (NN CYP) (NNS isozymes)) (-RRB- -RRB-))) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NN biotransformation)) (PP (IN of) (NP (NNS drugs))))))))))) (. .)))
(S1 (S (S (PP (IN By) (S (VP (VBG inhibiting) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NNS drugs))))))) (, ,) (NP (NN drug1)) (VP (VBZ improves) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NNS drugs)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (JJ dose-dependent) (JJ antinociceptive) (NN activity)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBN evaluated) (PP (IN by) (NP (CC both) (NP (NN drug3) (NN writhing)) (CC and) (NP (NN formalin) (NN test)))))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN plasma) (NN concentration)) (VP (VBD was) (ADVP (RB also)) (VP (VBN increased)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ synergistic) (NN antinociception) (NN activity)) (PP (IN of) (NP (NN drug1))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))) (VP (MD can) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (PP (IN From) (NP (DT this) (NN study))) (NP (PRP it)) (VP (MD can) (VP (VB be) (VP (VBN concluded) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN bioenhancer)) (PP (IN along) (PP (IN with) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Prevention)) (PP (IN of) (NP (NN emergence) (NN agitation))) (PP (IN in) (NP (NP (CD seven) (NNS children)) (VP (VBG receiving) (NP (NP (JJ low-dose) (NN drug1)) (CC and) (NP (NN drug2) (JJ total) (JJ intravenous) (NN anesthesia)))))) (. .))))
(S1 (S (S (NP (NP (NN Emergence) (NN agitation)) (PRN (-LRB- -LRB-) (NP (NN EA)) (-RRB- -RRB-))) (VP (MD can) (VP (VB be) (NP (NP (DT a) (JJ distressing) (JJ side) (NN effect)) (PP (IN of) (NP (JJ pediatric) (NNS anesthesia))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP retrospectively) (VP (VBN reviewed) (NP (NP (DT the) (NNS records)) (PP (IN of) (NP (NP (CD 7) (JJ pediatric) (NN oncology) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ low-dose) (NN drug1)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug2))))) (PP (IN for) (NP (NP (JJ total) (JJ intravenous) (NN anesthesia)) (PRN (-LRB- -LRB-) (NP (NN TIVA)) (-RRB- -RRB-))))) (ADVP (RB repeatedly)) (PP (IN for) (NP (NN radiation) (NN therapy)))))))))))) (. .)))
(S1 (S (S (NP (NN EA) (NNS signs)) (VP (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (DT all) (CD 7) (NNS patients))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NN drug1) (NN TIVA))))))) (CC but) (VP (VBD did) (RB not) (VP (VB recur) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (CD 123) (JJ subsequent) (NN anesthetics) (NNS sessions)) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (JJ low-dose) (NN drug2)) (VP (VBD was) (VP (VBN added) (PP (TO to) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT this)) (VP (VBP experience))))) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ low-dose) (NN drug1)) (VP (VBN added) (PP (TO to) (NP (NN drug2))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NN prevention)) (PP (IN of) (NP (NN EA))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NN EA)) (PP (IN with) (NP (NN drug3) (NN TIVA))))))))))))))))) (. .)))
(S1 (S (NP (NP (NN -LSB-Efficacy)) (PP (IN of) (NP (JJ fixed) (NN combination) (NN drug1) (: /) (NN drug2))) (PP (IN in) (NP (NP (JJ hospitalized) (NNS patients)) (PP (IN with) (NP (JJ hypertensive) (NN disease))))) (-RRB- -RSB-))))
(S1 (S (S (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN tolerability))) (PP (IN of) (NP (JJ fixed) (NN drug1) (: /) (NN drug2) (NN combination)))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (CD 86) (NNS patients)) (PP (IN with) (NP (JJ hypertensive) (NN disease))) (VP (VBN hospitalized) (PP (IN in) (NP (NP (NNS departments)) (PP (IN of) (NP (NP (JJ general) (JJ internal) (NN medicine)) (CC or) (NP (NN cardiology)))))))))))) (. .)))
(S1 (S (S (NP (DT All) (NNS patients)) (VP (VP (VBD had) (NP (NP (NNS indications)) (PP (IN for) (NP (JJ antihypertensive) (NN therapy))))) (CC and) (VP (VBD were) (VP (VBN randomized) (PP (CC either) (PP (TO to) (NP (NP (JJ fixed) (NN combination) (NN drug1)) (: /) (NP (NN drug2) (-LRB- -LRB-) (CD n=43) (-RRB- -RRB-)))) (CC or) (PP (TO to) (NP (NP (NN therapy)) (SBAR (WHNP (WDT which)) (S (VP (VBD corresponded) (PP (TO to) (NP (NP (DT the) (NN hospital) (NN formulary)) (PRN (-LRB- -LRB-) (NP (NN n=43)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Correction)) (PP (IN of) (NP (NN drug1) (NN therapy)))) (VP (VBD was) (VP (VBN performed) (PP (IN by) (S (VP (VBG treating) (NP (NN physician)) (PP (IN at) (NP (JJ daily) (NNS rounds))))))))) (. .)))
(S1 (S (S (NP (NP (NN Self-control)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN BP)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN performed) (PP (IN by) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN UA767PC) (NN apparatus)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Results)) (PP (IN of) (NP (NN BP) (NN self-control)))) (VP (VBD were) (VP (VBN compared) (PP (IN with) (NP (JJ clinical) (NNS measurements))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB detect) (NP (NP (VBN concealed) (NN inefficacy)) (PP (IN of) (NP (NN treatment))))))))))) (. .)))
(S1 (S (NP (NP (NNS Results)) (. .))))
(S1 (S (NP (NP (NN Rate)) (PP (IN of) (NP (NP (NN achievement)) (PP (IN of) (NP (NN target) (NN BP))) (PP (IN with) (NP (NP (JJ fixed) (NN combination) (NN drug1)) (: /) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (CD 93) (NN %)) (-RRB- -RRB-)))))))) (VP (VBD was) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT that)) (PP (IN on) (NP (NP (JJ traditional) (NN therapy)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (CC But) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ fixed) (NN combination) (NN drug1)) (: /) (NP (NP (NN drug2)) (VP (VBN compared) (PP (IN with) (NP (JJ traditional) (NN therapy)))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (ADJP (RBR lower) (JJ clinical)) (CC and) (ADJP (NN self) (VBD measured))) (NN BP)) (, ,) (NP (NP (JJ quicker) (NN achievement)) (PP (IN of) (NP (NP (NN target) (NN BP)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 5.8+/-2.3)) (CC and) (NP (CD 9.2+/-1.8) (NNS days))) (, ,) (ADVP (RB respectively)) (, ,) (NP (CD 0.05))) (-RRB- -RRB-))))) (, ,) (NP (NP (JJR lesser) (NN number)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2.5+/-0.6) (CC and) (CD 3.0+/-0.9)) (NNS days)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))))) (, ,) (NP (NP (JJR lower) (NN rate)) (PP (IN of) (NP (NP (VBN concealed) (NN inefficacy)) (PP (IN of) (NP (NP (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12) (CC and) (CD 31)) (NN %)) (, ,) (ADVP (RB respectively)) (, ,) (NP (CD 0.05))) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (NP (NP (NNS Conclusions)) (. .))))
(S1 (S (NP (PRP We)) (VP (VBP have) (VP (VBN demonstrated) (NP (NP (NN appropriateness)) (PP (IN of) (NP (NP (JJ inhospital) (NN administration)) (PP (IN of) (NP (JJ fixed) (NN drug1) (: /) (NN drug2) (NN combination)))))) (PP (IN as) (NP (NP (DT an) (NN approach)) (VP (VP (VBG allowing) (S (VP (TO to) (VP (VB achieve) (NP (NN target) (NN BP)) (PP (IN in) (NP (JJR shorter) (NN time))) (, ,) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJR fewer) (NNS drug3))))))))) (, ,) (CC and) (VP (VBG diminishing) (NP (NP (VBN concealed) (NN inefficacy)) (PP (IN of) (NP (NN treatment)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Antitumor) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN HB-EGF)))) (, ,))) (PP (IN in) (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NN leukemia))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ therapeutic) (NN outcome)) (PP (IN for) (NP (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN T-ALL)) (-RRB- -RRB-))))) (VP (VBZ remains) (ADJP (JJ poor)))) (: ;)))
(S1 (S (S (ADVP (RB thus)) (, ,) (NP (ADJP (ADJP (JJ novel)) (, ,) (ADJP (JJ targeted))) (NNS therapies)) (VP (VBP are) (ADVP (RB urgently)) (VP (VBN needed)))) (. .)))
(S1 (S (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NP (JJ heparin-binding) (JJ epidermal) (NN growth) (JJ factor-like) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN HB-EGF)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN member)) (PP (IN of) (NP (DT the) (NN EGF) (NN family)))) (, ,)) (VP (VBZ is) (NP (NP (DT a) (JJ promising) (NN target)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NN cancer))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBD was) (S (VP (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN HB-EGF)) (VP (VBZ is) (NP (NP (DT a) (JJ therapeutic) (NN target)) (PP (IN for) (NP (NN T-ALL))))))))) (, ,) (CC and) (VP (TO to) (ADVP (RB further)) (VP (VB elucidate) (NP (NP (DT the) (JJ antitumor) (NNS effects)) (PP (IN of) (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN HB-EGF)))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VP (VBN elucidated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN HB-EGF))) (PP (IN in) (NP (NN T-ALL) (NN cell) (NNS lines))))) (, ,) (CC and) (VP (VBD evaluated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (DT these) (NNS cells))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NP (NN EGFR)) (CC and) (NP (NN EGFR))) (NNS ligands)))) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP (NP (NN flow) (NN cytometry)) (, ,) (NP (NN RT-PCR)) (CC and) (NP (JJ real-time) (JJ quantitative) (NN PCR))))))) (. .)))
(S1 (S (S (NP (NP (NN Induction)) (PP (IN of) (NP (NN apoptosis)))) (VP (VBD was) (VP (VBN assessed) (PP (IN by) (NP (NN TUNEL) (NN assay)))))) (. .)))
(S1 (S (S (S (NP (NN HB-EGF)) (VP (VBD was) (ADVP (RB strongly)) (VP (VBN expressed) (PP (IN by) (NP (NN T-ALL) (NN cell) (NNS lines)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (CC both) (NP (NN HB-EGF)) (CC and) (NP (NN EGFR))))) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBD induced) (NP (NN apoptosis)))) (, ,) (CC and) (S (ADVP (RB furthermore)) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug2)) (CC plus) (NP (NN drug3))))) (VP (VBD enhanced) (NP (NN cytotoxicity)) (PP (IN in) (NP (DT a) (NN T-ALL) (NN cell) (NN line)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN HB-EGF)) (VP (VBZ is) (NP (NP (DT a) (JJ promising) (JJ therapeutic) (NN target)) (PP (IN for) (NP (NN T-ALL))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Distinct) (JJ synergistic) (NN action)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN against) (NP (FW Pseudomonas) (FW aeruginosa))))) (. .)))
(S1 (S (S (NP (DT The) (NN dicarbonyl) (NN compound) (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (JJ natural) (NN constituent)) (PP (IN of) (NP (NP (NN Manuka) (NN honey)) (VP (VBN produced) (PP (IN from) (NP (NP (NN Manuka) (NNS flowers)) (PP (IN in) (NP (JJ New) (NN Zealand))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB possess) (NP (ADJP (CC both) (ADJP (JJ anticancer)) (CC and) (ADJP (JJ antibacterial))) (NN activity)))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS observations)) (VP (VBD prompted) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN drug1)))) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN drug)) (PP (IN against) (NP (JJ multidrug) (JJ resistant) (NP (FW Pseudomonas) (FW aeruginosa))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 12)))) (VP (VB test) (NP (NN P)))) (. .)))
(S1 (S (S (NP (NP (FW aeruginosa) (NNS strains)) (VP (VBN isolated) (PP (IN from) (NP (JJ various) (NNS hospitals))))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (PRP$ their) (NNS resistances)) (PP (IN against) (NP (NP (JJ many) (NNS drug1)) (, ,) (SBAR (WHNP (NP (JJS most)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (VBN applied) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN P)))))))))))))))) (. .)))
(S1 (S (NP (NP (FW aeruginosa) (NNS infections)) (. .))))
(S1 (S (S (NP (NNS Results)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (NNS strains)) (VP (VBD were) (ADJP (JJ resistant) (PP (TO to) (NP (JJ many) (NNS drugs)))) (PP (IN at) (NP (JJ high) (NNS levels))) (, ,) (ADVP (RB only))))))) (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBD showed) (NP (NNS resistances)) (PP (IN at) (NP (ADJP (RB comparatively) (JJR lower)) (NNS levels))))) (. .)))
(S1 (S (S (PP (VBG Following) (NP (JJ multiple) (NNS experimentations))) (NP (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ antimicrobic) (PP (IN against) (NP (NP (PDT all) (DT the) (NNS strains)) (PP (IN at) (NP (JJ comparable) (NNS levels)))))))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Distinct)) (CC and) (ADJP (RB statistically) (JJ significant))) (NN synergism)) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN by) (NP (NN disc) (NN diffusion) (NNS tests))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (PRP$ their) (JJ individual) (NNS effects))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ fractional) (JJ inhibitory) (NN concentration) (NN index)) (PP (IN of) (NP (DT this) (NN combination))) (VP (VBN evaluated) (PP (IN by) (NP (NN checkerboard) (NN analysis)))) (, ,)) (VP (VBD was) (NP (NP (CD 0.5)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD confirmed) (NP (NP (NN synergism)) (PP (IN between) (NP (DT the) (NN pair)))))))))) (. .)))
(S1 (S (S (NP (NN Synergism)) (VP (VBD was) (ADVP (RB also)) (VP (VBN noted)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN combined) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN failure)) (PP (IN in) (NP (NP (DT an) (JJ HIV-positive) (NN woman)) (PP (IN on) (NP (NN drug2) (NN therapy)))))) (VP (VBG resulting) (PP (IN in) (NP (CD two) (JJ ectopic) (NNS pregnancies))))) (. .)))
(S1 (S (S (PP (IN Since) (NP (NP (PRP$ its) (NN introduction)) (PP (IN in) (NP (CD 1999))))) (, ,) (NP (NN drug1)) (VP (VBZ remains) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ preferred) (JJ contraceptive) (NNS choices)) (PP (IN for) (NP (JJ many) (NNS women)))))) (SBAR (IN as) (S (NP (PRP it)) (VP (VBZ offers) (NP (NP (DT a) (ADJP (RB highly) (JJ effective)) (NN means)) (PP (IN of) (NP (JJ long-term) (NN contraception))) (PP (IN for) (NP (CD three) (NNS years))) (SBAR (WHNP (WDT that)) (S (VP (VBZ does) (RB not) (VP (VB rely) (PP (IN on) (NP (NN adherence))))))))))))) (. .)))
(S1 (S (S (PP (IN Like) (NP (DT all) (NN drug1))) (, ,) (NP (JJ certain) (JJ hepatic) (JJ enzyme-inducing) (NNS drugs)) (VP (MD may) (VP (VB reduce) (NP (PRP$ its) (NN efficacy))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT an) (JJ interesting) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ HIV-positive) (NN woman)) (PP (IN on) (NP (NP (NN drug1) (NN therapy)) (VP (VBG having) (NP (JJ tubal) (NNS pregnancies)) (PP (IN on) (NP (NP (CD two) (JJ separate) (NNS occasions)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NN place)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN CYP) (NN 2D6))) (NNS inhibitors)) (: :) (NP (NN caution))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT an) (NN drug2)) (, ,)) (VP (VBZ is) (NP (NP (DT the) (JJ standard) (NN hormone) (NN treatment)) (PP (IN for) (NP (NN breast) (NN cancer)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB extensively)) (VP (VBN transformed) (PP (IN into) (NP (PRP$ its) (JJ active) (NNS metabolites))) (PP (IN by) (NP (DT the) (NP (NN cytochrome) (NN P450)) (NN enzyme) (NN system))) (, ,) (ADVP (RB especially)) (PP (IN into) (NP (NN drug1))) (PP (IN by) (NP (NN isoenzyme) (NN CYP) (NN 2D6)))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ isoenzyme) (NN CYP) (NN 2D6) (NNS inhibitors)))) (VP (VBZ reduces) (NP (DT this) (NN metabolism)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP inhibit) (NP (NN isoenzyme) (NN CYP) (NN 2D6)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP reduce) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug3)))) (PP (IN by) (NP (QP (RB about) (CD 50)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (CD Two) (JJ epidemiological) (NNS studies)) (VP (VBG involving) (NP (QP (RB about) (CD 3700)) (NNS women)))) (VP (VBP have) (VP (VBN shown) (NP (NP (DT a) (NN link)) (PP (IN between) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT an) (VBN increased) (NN frequency)) (PP (IN of) (NP (NN breast) (NN cancer) (NN recurrence)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS studies)) (, ,) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN level)) (PP (IN of) (NP (NN evidence))))) (, ,)) (VP (VBD were) (ADJP (RBR less) (JJ convincing)))) (. .)))
(S1 (S (S (S (NP (NP (NNS Studies)) (PP (IN of) (NP (JJ other) (JJ isoenzyme) (NN CYP) (NN 2D6) (NNS inhibitors)))) (VP (VBD showed) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN breast) (NN cancer) (NN recurrence)))))))) (, ,) (CC but) (S (NP (PRP they)) (VP (VBD lacked) (NP (JJ statistical) (NN power))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB better)) (S (VP (TO to) (VP (VB avoid) (NP (JJ prescribing) (JJ isoenzyme) (NN CYP) (NN 2D6) (NNS inhibitors)) (PP (TO to) (NP (NP (NP (NNS women)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (PP (IN for) (NP (NN breast) (NN cancer))))))) (, ,) (ADVP (RB especially)) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (S (NP (NN Depression)) (VP (VBZ does) (RB not) (ADVP (RB always)) (VP (VB require) (NP (NN drug1) (NN therapy))))) (, ,) (CC and) (S (NP (NNS drug2)) (VP (VBP have) (NP (DT no) (JJ proven) (JJ preventive) (NN impact)) (PP (IN on) (NP (NP (JJ hot) (NNS flushes)) (VP (VBN linked) (PP (TO to) (NP (DT the) (NN menopause))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (PP (IN in) (NP (JJ certain) (NNS cases))) (, ,) (NP (DT an) (NN drug1)) (VP (VBZ is) (VP (VBN considered) (ADJP (JJ necessary)))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB replace) (NP (NN drug2)) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Phase) (NN I) (NN trial)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ relapsed) (JJ multiple) (NN myeloma)))))) (: :) (NP (NP (NN evidence)) (PP (IN for) (NP (NN drug3)))) (: -) (NP (NP (NN drug4) (NN interaction)) (PP (IN via) (NP (NN P-glycoprotein)))) (. .))))
(S1 (S (S (NP (NP (JJ Multiple) (NN myeloma)) (PRN (-LRB- -LRB-) (NP (NN MM)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT an) (JJ incurable) (NN plasma-cell) (NN neoplasm)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (JJS most) (NNS treatments)) (VP (VBP involve) (NP (NP (DT a) (JJ therapeutic) (NN agent)) (VP (VBN combined) (PP (IN with) (NP (NN drug1))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ preclinical) (NN combination)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (DT the) (NN mTOR) (NN inhibitor) (NN drug2)))) (VP (VBZ has) (VP (VBD displayed) (NP (NN synergy)) (ADVP (FW in) (FW vitro))) (CC and) (VP (VBZ represents) (NP (DT a) (JJ novel) (NN combination)) (PP (IN in) (NP (NN MM)))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vivo)) (NN CYP3A) (NN activity)) (VP (VBZ is) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NN drug1) (JJ -treated)))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NN drug2) (JJ -treated) (JJ renal) (NN allograft) (NNS recipients)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN identified) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (PP (IN as) (NP (NN CYP3A) (NNS inhibitors)))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT the) (JJ current) (NN study)) (PP (IN in) (NP (JJ renal) (NN allograft) (NNS recipients))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (ADJP (ADVP (ADVP (RB intravenously)) (CC and) (ADVP (RB orally))) (VBN administered)) (NN drug1)) (PP (IN as) (NP (DT a) (NN drug) (NN probe))) (S (VP (TO to) (VP (VB assess) (SBAR (IN whether) (S (NP (NP (DT the) (NN study) (NNS drugs)) (PP (IN at) (NP (NP (NNS doses)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB generally)) (VP (VBN used) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))) (VP (VBP have) (NP (JJ differential) (NNS effects)) (PP (IN on) (NP (ADJP (FW in) (FW vivo)) (ADJP (ADJP (JJ hepatic)) (CC and) (ADJP (JJ first-pass))) (NN CYP3A) (NNS activities)))))))))) (. .)))
(S1 (S (S (NP (ADJP (ADJP (JJ Systemic)) (CC and) (ADJP (JJ apparent) (JJ oral))) (NN drug1) (NN clearance)) (VP (VBD were) (NP (NP (NP (CD 24) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 269) (QP (CD 73) (CC vs.) (CD 354) (CD 102)) (NN ml/min)) (, ,) (NP (NN P) (JJ =) (NN 0.022)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 31) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 479) (QP (CD 190) (CC vs.) (CD 688) (CD 265)) (NN ml/min)) (, ,) (NP (NN P) (JJ =) (NN 0.013)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)) (, ,) (ADJP (ADJP (JJR lower) (PP (IN in) (NP (NP (JJ drug2) (JJ -treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 20)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN in) (NP (NP (JJ matched) (NN drug3) (JJ -treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 20)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ latter)) (VP (VBD displayed) (NP (NP (NN drug1) (NNS clearances)) (ADJP (JJ similar) (PP (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (NP (CD two) (JJR larger) (NNS cohorts)) (PP (IN of) (NP (NP (JJ nonmatched) (NN drug2) (JJ -treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 58)) (CC and) (NP (NN n) (JJ =) (CD 80)) (-RRB- -RRB-)))))))) (CC and) (PP (TO to) (NP (NP (DT those)) (VP (VBG receiving) (NP (NP (DT a) (ADJP (NN drug3) (JJ -free)) (NN regimen)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 6)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ implies) (SBAR (IN that) (S (NP (ADJP (FW in) (FW vivo)) (ADJP (ADJP (JJ hepatic)) (CC and) (ADJP (JJ first-pass))) (NN CYP3A) (NNS activities)) (VP (VBP are) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (VP (VBG receiving) (NP (NN drug2))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (, ,) (PP (IN at) (NP (NP (DT the) (NNS doses)) (VP (ADVP (RB generally)) (VBN used) (PP (IN in) (NP (JJ clinical) (NN practice)))))) (, ,) (NP (NN drug3)) (VP (VBZ is) (NP (NP (DT the) (JJR stronger)) (PP (IN of) (NP (DT the) (CD two))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NN CYP3A) (NN inhibition)))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN observation)) (VP (VBZ has) (NP (JJ important) (NNS implications)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (JJ drug-drug) (NNS interactions)) (PP (IN in) (NP (NN transplant) (NNS recipients))))))))) (. .)))
(S1 (S (S (NP (NP (NN -LSB-Influence)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN on) (NP (NP (JJ MPTP-evoked) (NN behavior) (NNS violations)) (PP (IN in) (NP (NN C57BL/6) (NNS mice)))))) (-RRB- -RSB-)) (. .)))
(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ drug1) (NN drug2)) (PRN (-LRB- -LSB-) (NP (NN drug3)) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg)) (, ,) (NP (NP (FW p.) (NN o)) (. .))) (-RRB- -RRB-)))))))
(S1 (S (NP (NP (NP (CC and/or) (NP (NP (NN drug1) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg)) (, ,) (NP (NNP p.) (NNP o.))) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT that)) (PP (IN of) (NP (NN neurotoxin) (NN drug3))))) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4) (CC x) (CD 20)) (NN mg/kg)) (, ,) (NP (NN i.) (NN p)) (. .)) (-RRB- -RRB-)))))
(S1 (S (S (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (NP (ADJP (ADJP (JJ elevated)) (CC plus) (ADJP (JJ maze))) (NN test)) (PP (IN on) (NP (NN C57BL/6) (NNS mice)))))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NP (JJ second) (NN day)) (PP (IN after) (NP (NN injection))))) (, ,) (NP (NN drug1)) (VP (VBD decreased) (NP (NP (DT the) (NP (NN locomot)) (CC or) (NP (NN activity))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NN saline)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Acute) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBD failed) (S (VP (TO to) (VP (VB influence) (NP (NP (NN locomotion)) (PP (IN in) (NP (NNS mice))))))) (, ,) (SBAR (IN while) (S (NP (PRP$ their) (NN combination)) (VP (VBN normalized) (NP (NN motor) (NN activity))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (VP (VBP confirm) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ inflammatory) (NNS processes))) (PP (IN in) (NP (NN parkinsonism))))) (CC and) (VP (VBP suggest) (NP (NP (NN expediency)) (PP (IN of) (NP (NP (JJ combined) (NN pharmacotherapy)) (PP (IN of) (NP (JJ neurodegenerative) (NNS diseases))))))))) (. .)))
(S1 (S (S (NP (NP (NN Exposure)) (PP (TO to) (NP (JJ oral) (NN drug1)))) (VP (VBZ is) (UCP (ADJP (JJ unaffected) (PP (IN by) (NP (NN drug2)))) (CC but) (VP (ADVP (RB greatly)) (VBN increased) (PP (IN by) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (JJ drug-drug) (NNS interactions)) (PP (IN of) (NP (JJ oral) (NN drug1))) (PP (IN with) (NP (NP (DT the) (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NN 2B6) (NN inhibitor) (NN drug2)) (CC and) (NP (DT the) (NN CYP3A) (NN inhibitor) (NN drug3))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT this) (ADJP (ADJP (JJ randomized)) (, ,) (ADJP (JJ blinded)) (, ,) (ADJP (JJ crossover))) (NN study))) (, ,) (NP (CD 11) (JJ healthy) (NNS volunteers)) (VP (VBN ingested) (NP (NP (ADJP (CD 0.2) (NN mg/kg)) (NN drug1)) (PP (IN after) (NP (NP (NNS pretreatments)) (PP (IN with) (NP (NP (NP (JJ oral) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 250) (NN mg)) (ADVP (RB twice) (RB daily))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NN placebo)))))) (PP (IN in) (NP (JJ 6-day) (NN treatment) (NNS periods)))) (PP (IN at) (NP (NP (NNS intervals)) (PP (IN of) (NP (CD 4) (NNS weeks)))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN treatment)) (VP (VBD increased) (NP (NP (NP (NP (DT the) (JJ mean) (NN area)) (PP (IN under) (NP (NP (DT the) (NN plasma) (NN concentration-time) (NN curve)) (VP (VBN extrapolated) (PP (TO to) (NP (NN infinity))))))) (PRN (-LRB- -LRB-) (NP (NN AUC) (-LRB- -LRB-) (CD 0-) (-RRB- -RRB-)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ oral) (NN drug2)))) (PP (IN by) (NP (RB 2.4-fold))) (, ,) (SBAR (IN whereas) (S (NP (NN drug3) (NN treatment)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (DT the) (NN exposure)) (PP (TO to) (NP (NN drug4)))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (NP (NN drug1) (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 0-)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NN drug2) (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 0-)) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN in) (NP (DT the) (NN drug3))) (PRN (-LRB- -LRB-) (NP (NP (NN P) (NN &amp)) (: ;) (NP (NN lt)) (: ;) (NP (CD 0.001))) (-RRB- -RRB-)) (PP (IN drug4) (NP (NP (JJ zole) (NNS phases)) (PRN (-LRB- -LRB-) (NP (NN P) (JJ =) (CD 0.006)) (-RRB- -RRB-)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NN placebo)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (NN drug1) (CC and) (NN drug2) (NNS phases))) (, ,) (NP (NP (DT the) (NNS areas)) (PP (IN under) (NP (NP (DT the) (JJ effect-time) (NNS curves)) (PRN (-LRB- -LRB-) (NP (NP (JJ self-reported) (NN drowsiness)) (CC and) (NP (NN performance))) (-RRB- -RRB-))))) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN placebo) (NN phase))) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (CD &lt) (: ;) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ different) (NNS drug2)))) (VP (VBZ is) (ADJP (JJ antagonistic) (PP (PP (IN in) (NP (NN breast))) (CC but) (PP (RB not) (IN in) (NP (JJ other) (NN cancer) (NNS cells))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN cyclooxygenase-2)))) (, ,)) (VP (VBZ is) (VP (VBG being) (VP (VBN investigated) (PP (IN for) (NP (NP (NN enhancement)) (PP (IN of) (NP (NN chemotherapy) (NN efficacy))) (PP (IN in) (NP (NN cancer) (JJ clinical) (NNS trials))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ investigates) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN drug1))) (S (VP (TO to) (VP (VB sensitize) (NP (NP (NNS cells)) (PP (IN from) (NP (JJ different) (NNS origins)))) (PP (TO to) (NP (JJ several) (NNS drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NP (DT the) (NN drug) (POS 's)) (NN mechanism)) (PP (IN of) (NP (NP (NP (NN action)) (CC and) (NP (NN sequence))) (PP (IN of) (NP (NN administration)))))))) (VP (VBP are) (ADVP (RB also)) (VP (VBN investigated)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN sensitivity)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis)) (CC and) (NP (NN DNA) (NN damage))) (PP (IN of) (NP (NP (CD five) (JJ different) (NN cancer) (NN cell) (NNS lines)) (-LRB- -LRB-) (NP (NP (NN HeLa)) (, ,) (NP (NN HCT116)) (, ,) (NP (NN HepG2)) (, ,) (NP (NN MCF7)) (CC and) (NP (NN U251))) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4) (NN drug5) (JJ following) (JJ different) (NN incubation) (NNS schedules))))) (VP (VBD were) (VP (VBN analyzed)))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (NN antagonism)) (PP (PP (IN between) (NP (NP (NP (NN drug1)) (CC and) (NP (DT the) (CD four) (NNS drugs))) (PP (IN in) (NP (NP (DT the) (NN breast) (NN cancer) (NNS cells)) (VP (ADVP (RB MCF7)) (VBG following) (NP (DT all) (NN incubation) (NNS schedules))))))) (CC and) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (PP (IN in) (NP (DT all) (NN cell) (NNS lines))) (PP (IN except) (PP (IN for) (NP (NP (CD two) (NNS combinations)) (PP (IN in) (NP (NN HCT116) (NNS cells))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN with) (NP (DT the) (JJ other) (CD three) (NNS drugs))) (PP (IN in) (NP (DT the) (VBG remaining) (CD four) (NN cell) (NNS lines)))) (VP (VBD resulted) (PP (IN in) (NP (JJ variable) (NNS interactions))))) (. .)))
(S1 (S (S (NP (JJ Mechanistic) (NNS investigations)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ exerts) (NP (JJ different) (JJ molecular) (NNS effects)) (PP (IN in) (NP (JJ different) (NNS cells)))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT some) (NNS lines))) (, ,) (NP (PRP it)) (VP (VBZ abrogates) (NP (NP (DT the) (JJ drug-induced) (NN G2/M) (NN arrest)) (VP (VBG enhancing) (NP (NP (NN pre-mature) (NN entry)) (PP (IN into) (NP (NN mitosis))) (PP (IN with) (NP (JJ damaged) (NN DNA)))))) (S (ADVP (RB thus)) (VP (VP (VBG increasing) (NP (NN apoptosis))) (CC and) (VP (VBG resulting) (PP (IN in) (NP (NN synergism))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ other) (NNS cells))) (, ,) (NP (PRP it)) (VP (VBZ enhances) (NP (NP (JJ drug-induced) (NN G2/M) (NN arrest)) (VP (VP (VBG allowing) (NP (NP (NN time)) (PP (TO to) (NP (NN repair) (JJ drug-induced) (NN DNA) (NN damage))) (PP (IN before) (NP (NP (NN entry)) (PP (IN into) (NP (NN mitosis))))))) (CC and) (VP (VBG decreasing) (NP (NP (NN cell) (NN death)) (VP (VBG resulting) (PP (IN in) (NP (NN antagonism))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT some) (JJ synergistic) (NNS combinations))) (, ,) (NP (NP (JJ celecoxib-induced) (NN abrogation)) (PP (IN of) (NP (NN G2/M) (NN arrest)))) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN apoptosis)) (CC but) (NP (JJ permanent) (NN arrest))) (PP (IN in) (NP (NN G1) (NN phase)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (, ,) (SBAR (IN if) (S (VP (VBN confirmed) (NP (NN in-vivo))))) (, ,) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (NP (DT a) (JJ suitable) (NN chemosensitizer)) (PP (PP (IN for) (NP (NN breast) (NN cancer))) (CC or) (PP (IN with) (NP (NP (NN drug2)) (PP (IN for) (NP (JJ other) (NNS cancers)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN combination)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN tailored) (PP (TO to) (NP (NP (DT the) (NN tumor) (NN type)) (, ,) (NP (NN drug)) (CC and) (NP (NN administration)) (NP (NN schedule)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NN drug2) (NN interaction))) (CC and) (VP (VBD associated) (NP (JJ gastrointestinal) (JJ bleeding) (NN risk)) (PP (IN in) (NP (DT a) (JJ case-control) (NN study))))) (. .)))
(S1 (S (S (NP (JJ Bleeding)) (VP (VBZ is) (NP (NP (DT the) (ADJP (ADJP (RBS most) (JJ common)) (CC and) (ADJP (NN worrisome) (JJ adverse))) (NN effect)) (PP (IN of) (NP (NN drug1) (NN therapy)))))) (. .)))
(S1 (S (S (NP (NP (CD One)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB increase) (NP (JJ bleeding) (NN risk))))))))) (VP (VBZ is) (NP (NP (NN initiation)) (PP (IN of) (NP (NN interacting) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VB potentiate) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD sought) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (NP (NN initiation)) (PP (IN of) (NP (DT an) (NN drug1)))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hospitalization))) (PP (IN for) (NP (NP (JJ gastrointestinal) (JJ bleeding)) (PP (IN in) (NP (NN drug2) (NNS users)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Medicaid) (NN claims) (NNS data)) (PRN (-LRB- -LRB-) (NP (NN 1999-2005)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB perform) (NP (NP (DT an) (JJ observational) (JJ case-control) (NN study)) (VP (VBN nested) (PP (IN within) (NP (NP (NN person-time)) (VP (VBN exposed) (PP (TO to) (NP (NN drug1))) (PP (IN in) (NP (DT those) (CD 18) (NNS years)))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN total))) (, ,) (NP (NN 430,455) (NN drug1) (NNS users)) (VP (VBD contributed) (NP (NP (CD 407,370) (NNS person-years)) (PP (IN of) (NP (NN drug2) (NN use)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN incidence) (NN rate)) (PP (IN of) (NP (NP (NN hospitalization)) (PP (IN for) (NP (JJ GI) (JJ bleeding))) (PP (IN among) (NP (NN drug1) (NNS users)))))) (VP (VBD was) (NP (QP (CD 4.48) (IN per) (CD 100)) (NNS person-years)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI)) (, ,) (NP (CD 4.42-4.55)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (DT Each) (JJ gastrointestinal) (JJ bleeding) (NNS cases)) (VP (VBD was) (VP (VBN matched) (PP (TO to) (NP (NP (CD 50) (NNS controls)) (VP (VBN based) (PP (IN on) (NP (NP (NN index) (NN date)) (CC and) (NP (NN state)))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS users)) (VP (VBD had) (NP (NP (DT an) (VBN increased) (NNS odds) (NN ratio)) (PP (IN of) (NP (JJ gastrointestinal) (JJ bleeding)))) (PP (IN upon) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (ADJP (JJ =) (NP (CD 1.73))) (ADJP (CD -LSB-95) (NN %)) (NN CI)) (, ,) (NP (CD 1.25-2.38) (-RRB- -RSB-))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (ADJP (JJ =) (NP (CD 1.63))) (ADJP (CD -LSB-95) (NN %)) (NN CI)) (, ,) (NP (CD 1.11-2.38) (-RRB- -RSB-))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (ADJP (JJ =) (NP (CD 1.64))) (ADJP (CD -LSB-95) (NN %)) (NN CI)) (, ,) (NP (CD 1.27-2.12) (-RRB- -RSB-))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (CC OR) (NP (JJ =) (NP (NN 1.47) (CD -LSB-95) (NN %)) (CD CI) (, ,) (CD 1.02-2.11) (-RRB- -RSB-)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (RB not) (VP (VBN believed) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NNS drug2)))))))))) (, ,)) (VP (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ GI) (JJ bleeding))) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (ADJP (JJ =) (NP (CD 1.75) (CD -LSB-95) (NN %))) (NN CI)) (, ,) (NP (CD 1.30-2.35) (-RRB- -RSB-))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS users)) (SBAR (WHNP (WP who)) (S (VP (VBD initiated) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))))))) (VP (VBD had) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN hospitalization))) (PP (IN for) (NP (JJ gastrointestinal) (JJ bleeding)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ elevated) (NN risk)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT a) (JJ drug-drug) (NN interaction)) (VP (MD may) (RB not) (VP (VBP have) (VP (VBN been) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (VBN observed) (VBN increased) (NN risk))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ enhances) (NP (NP (DT the) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NNS mice)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (ADJP (RB highly) (JJ selective)) (NN alpha-2-adrenoceptor) (NN agonist)) (, ,)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN introduced) (PP (IN into) (NP (NP (JJ clinical) (NN practice)) (PP (IN for) (NP (PRP$ its) (ADJP (ADJP (JJ sedative)) (CC and) (ADJP (JJ analgesic))) (NNS properties)))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (DT the) (JJ psychostimulant) (NN drug) (NN drug1)) (VP (VBZ has) (NP (NP (DT any) (NN effect)) (PP (IN on) (NP (NP (JJ drug2) (JJ -induced) (NN antinociception)) (CC and) (NP (NN locomotor) (NN inhibitor) (NN activity)))) (PP (IN in) (NP (NNS mice)))) (PP (IN in) (NP (JJ acute) (NN application)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT both) (NNS sexes)) (PP (IN of) (NP (NN swiss) (NN albino) (NNS mice))))) (: ;)))
(S1 (S (S (S (NP (NN antinociception)) (VP (VBD was) (VP (VBN assessed) (PP (IN with) (NP (JJ hot-plate) (NN test)))))) (CC and) (S (NP (DT the) (ADJP (ADJP (JJ locomotor)) (, ,) (ADJP (JJ exploratory))) (NNS activities)) (VP (VBD were) (VP (VBN assessed) (PP (IN with) (NP (JJ holed) (JJ open) (NN field) (NN test))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS animals)) (VP (VBD were) (VP (VBN received)))) (: ;)))
(S1 (S (NP (NP (NP (NP (NN saline)) (CC +) (NP (NN saline))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (CC +) (NP (NP (NP (NP (NP (NP (NP (NN saline)) (, ,) (NP (NN saline)) (CC +) (NP (NN drug2))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN g/kg)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (CC +) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN g/kg)) (-RRB- -RRB-)))) (, ,) (ADVP (RB intraperitoneally)) (, ,) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NP (JJ hot) (NN plate)) (CC or) (NP (JJ holed) (JJ open) (NN field) (NNS tests))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (DT the) (JJ hot) (NN plate) (NN test)) (PP (IN in) (NP (NNS mice))))) (, ,) (NP (NP (NN co-administration)) (PP (IN of) (NP (CD 15) (NN g/kg) (NN drug1))) (PP (IN with) (NP (ADJP (CD 10) (NN mg/kg)) (NN drug2)))) (VP (CONJP (RB intraperitoneally) (RB not) (RB only)) (VP (VBD enhanced)) (, ,) (CONJP (CC but) (RB also)) (VP (VBD prolonged) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN antinociception)) (VP (VBN induced) (PP (IN by) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (NP (DT the) (JJ locomotor) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN counteracted) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD concluded) (SBAR (IN that) (S (NP (NP (DT the) (JJ combined) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB have) (NP (JJ beneficial) (NNS effects)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN pain))))) (PP (IN without) (S (VP (VBG causing) (NP (NP (NN sedation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ limits) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug3)))) (PP (IN as) (NP (NP (DT an) (NN drug4)) (PP (IN in) (NP (NNS humans)))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction) (NN study)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN with) (NP (VBN co-administered) (NNS drugs))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (ADVP (RB drug3)) (VP (VBN used) (PP (IN in) (S (VP (VBG treating) (NP (ADJP (ADJP (JJ urinary)) (CC and) (ADJP (JJ respiratory))) (NN tract) (NNS infections)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB have) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ active)) (PP (IN in) (NP (NN gastro) (JJ intestinal) (NN tract))))))))))))))) (. .)))
(S1 (S (S (PP (VBG Being) (NP (NP (NN drug1)) (CC and) (NP (NN lomefloxacin)) (NP (NN drug2)))) (NP (NP (DT the) (NN interaction) (NN study)) (PP (IN of))) (VP (VBD was) (VP (VBN carried) (PRT (RP out)) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))))) (. .)))
(S1 (S (S (NP (DT The) (NN interaction)) (VP (VBD was) (VP (VBN studied) (PP (PP (IN at) (NP (ADJP (ADJP (JJ neutral)) (, ,) (ADJP (JJ acidic)) (CC and) (ADJP (JJ basic))) (NNS conditions))) (CC both) (PP (IN at) (NP (NP (JJ room) (NN temperature)) (CC and) (NP (CD 37) (NN C)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN dissolution) (NN medium)) (VP (VBG simulating) (NP (JJ various) (NN body) (NNS environments)) (PP (IN with) (NP (NP (NN response)) (PP (TO to) (NP (NN pH))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN examined) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (DT the) (NNS interactions)))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN after) (NP (NP (NP (NN interaction)) (PP (IN with) (NP (NN co-administered) (NNS drugs))) (PP (IN at) (NP (JJ different) (NNS conditions)))) (CC and) (NP (NN temperature))))) (VP (VBD were) (VP (VBN noted) (S (VP (VBG using) (NP (NP (DT a) (NN Shimadzu) (NN HPLC) (NN system)) (PP (IN with) (NP (NN PDA) (NN detector)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN seen) (SBAR (IN that) (S (NP (NP (NN interaction)) (PP (IN of) (NP (DT these) (NNS drug1)))) (VP (VBD was) (ADJP (RBR more)) (PP (IN at) (NP (CD 37) (NN C))) (PP (IN than) (PP (IN at) (NP (JJ room) (NN temperature)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBZ reacts) (ADVP (JJR faster)) (PP (IN with) (NP (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN in) (NP (NP (JJ acidic) (NNS media)) (CONJP (IN whereas) (IN with)) (NP (NP (NN drug5)) (PP (IN in) (NP (NP (JJ basic) (NNS media)) (CC and) (NP (NN drug6)))) (PP (IN in) (NP (JJ neutral) (NNS media))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN study)) (VP (VBZ ensures) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (VBN selected) (NN class)) (PP (IN of) (NP (NNS drugs)))))))) (. .)))
(S1 (S (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT the) (ADJP (JJ effective) (JJ therapeutic)) (NN effect) (JJ appropriate) (NN time) (NNS intervals)) (PP (IN between) (NP (NP (NNS administrations)) (PP (IN of) (NP (NNS drugs)))))))))) (VP (VBZ is) (ADJP (JJ essential)))) (. .)))
